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ABSTRACT 
Relationship between smoking marihuana and a drop in intraocular pressure (IOP) was 
first reported in 1971. Research efforts since then have identified a number of constituents that 
could be linked to this observation. Δ9-Tetrahydrocannabinol (THC) was one of the ingredients 
identified. However, four decades and numerous research efforts since the first observation, it 
has still not been concluded whether THC is effective in the treatment of glaucoma or not. 
Current therapy for IOP control in glaucoma, though effective, cannot prevent vision loss 
completely. Thus, identification of agents that can lower IOP as well as protect the retinal 
ganglion cells from apoptosis could yield a new class of anti-glaucoma molecules. Protection of 
retinal ganglion cells against apoptosis could yield a new class of antiglaucoma agents. 
Numerous investigations have demonstrated that THC also acts as a neuroprotective agent 
making it a very promising lead compound. However noninvasive delivery of THC to the 
targeted intraocular tissues is challenging due to its poor physiochemical properties.  
The aim of the current project was to effectively deliver THC to the intraocular tissues. 
THC prodrugs were synthesized to improve physicochemical properties. Preformulation 
characterization and formulation development for the THC prodrugs was undertaken. A high 
throughput in vitro model to screen the various formulations for transcorneal permeability was 
also developed. Promising formulations were instilled in vivo in anesthetized rabbit model and 
tissue concentrations were determined. Earlier formulations reported in the literature, used for 
determining efficacy were not observed to deliver THC to the targeted intraocular tissues. The 
formulations developed in this study were able to deliver significantly higher concentrations to 
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the intraocular tissues. Future studies need to investigate if these improved formulations of THC 
demonstrate pharmacological activity against glaucoma.  
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1.1 Anatomy of the eye 
The eye, responsible for vision, is one of the most important organs in the human body. It 
is roughly spherical in shape and averages about 22.4 mm across. The anterior chamber of the 
eye consists of the cornea, aqueous humor, iris-ciliary body and the lens while the posterior 
segment consists of the vitreous humor, retina and the sclera (Fig. 1-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1: Schematic representation of the eye.  
 Adapted from National Eye Institute, National Institutes of Health 
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1.1.1. Cornea 
The cornea is a multilayered structure composed of lipophilic epithelium and 
endothelium with a hydrophilic stromal layer sandwiched between them. The corneal epithelium 
represents the major barrier for transcorneal diffusion (Fig. 1-2). The epithelium in turn is 
composed of 4-5 cell layers. The uppermost layer consists of squamous cells (polygonal cells) 
followed by the wing cell and basal cell layers. The squamous layer is tightly linked together by 
continuous intercellular junctions(1). Transmembrane proteins, claudins and occludins form the 
tight junctions between the cells. These tight junctions act as a barrier to the passage of 
hydrophilic molecules through the intercellular spaces. The squamous layer also contains 
microvilli which is responsible for tear film stability. The basal cells layer is made up of 
columnar cells that replace the epithelial cell layer by undergoing mitotic division. Underlying 
the epithelium is a layer of collagen fibers, known as the Bowman’s membrane, which also 
restricts permeability of drug molecules(2). The stroma is hydrophilic in nature and is quite 
porus allowing passage of large hydrophilic molecules. The stroma consists of 90% water. 
Because of its hydrophilic nature, the stroma acts as a barrier for lipophilic molecules(3). The 
endothelium does not possess significant barrier properties, allowing even large molecules to 
pass through it.  
 
 
 
Figure 1-2: Schematic representation of the different lavers of the cornea.  
Reproduced with permission, ref (4) 
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1.1.2. Aqueous Humor 
The aqueous humor is a clear transparent liquid present between the lens and the cornea. 
It forms an important part of the eyes optical system. The chamber containing the aqueous humor 
is divided into two portions namely the anterior chamber and the posterior chamber by the iris. 
The aqueous humor is produced in the posterior chamber by the iris ciliary body and flows over 
the lens through the opening in the iris to the anterior chamber. It is then drained by the 
uveoscleral outflow or through the trabecular meshwork in the Schlemm`s canal(5). Aqueous 
humor production and drainage in the eye has been represented in Fig. 1-3. The total volume of 
aqueous humor in the anterior chamber is 200-300 µL and the turnover of aqueous humor in the 
eye is 2.4 ± 0.6 µL/min(6). The main functions of the aqueous humor are nourishment and waste 
removal of the tissues it comes in contact and maintenance of intraocular pressure.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3: Schematic representation of the aqueous humor formation and drainage in the eye.  
Adapted from the National Eye Institute, National Institutes of Health.  
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1.1.3. Iris Ciliary Body 
The iris divides the chamber containing the aqueous humor of the eye into anterior 
chamber and the posterior chamber. The amount of melanin present in the iris defines the color. 
There is no epithelium present on the iris. The sphincter and the dilator muscles in the iris let it 
close or open depending on the light conditions.  
 
 
 
 
 
 
 
 
 
Figure 1-4: Ciliary processes present on the ciliary body.  
Reproduced with permission, Ref (7) 
 
The ciliary body plays an important role in aqueous humor production and drainage. The 
ciliary body consists of ciliary muscle and ciliary processes with basal and later indigitation are 
present on the surface of the ciliary body (Fig. 1-4)(5). The epithelium of the ciliary process 
consists of an outer pigmented layer and an inner non-pigmented layer. The aqueous humor is 
produced by the inner non pigmented layer. There are two major pathways for the drainage of 
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aqueous humor from the anterior ocular segment: drainage through the Schlemm’s canal or the 
uveoscleral route. The major outflow pathway for the aqueous humor is drainage through the 
schlemm’s canal. The trabecular meshwork (TM), a mesh like structure present in front of the 
schlemm’s canal, presents the major resistance to the outflow of aqueous humor(8). Ligaments 
from the ciliary muscle extend into the TM and contraction/relaxation of the ciliary muscle leads 
to modulation of the intercellular spaces in the TM, and thus aqueous humor outflow(8). The 
non-pigmented ciliary epithelium forms the blood aqueous barrier with the vascular endothelium 
of retinal blood vessels.  
1.1.4. Vitreous Humor 
The vitreous humor is a clear extracellular matrix with gel like consistency present in the 
posterior chamber of the eye. It is present between the lens and the inner limiting lamina of the 
retina. The pH of vitreous humor is about 7.5 and is largely devoid of any cellular material. It 
occupies about 80% of the total volume of the eye. A meshwork of collagen fibrils (12-15 nm in 
diameter) lead to the gel like consistency of the vitreous humor. Hyaluronic acid, a mojor 
component of vitreous humor, occupies the space between the collagen fibers(9).  
1.1.5. Retina 
Light is focused by the cornea and the lens on the retina which converts it into a neural 
signal that is processed as an image by the brain. A schematic representation of the retina is 
depicted in Fig. 1-5. The retina is divided into the retinal pigmented epithelium and the neural 
retina. The retinal pigmented epithelium consists of cuboidal epithelium cells (Fig. 1-6). 
Choriocapalliries are leaky and usually allow drugs to equilibrate in the choroidal extracellular 
space. However, tight junctional proteins are present between the cuboidal cells forming a tight 
barrier known as the outer blood retinal barrier(10, 11).  
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Figure 1-5: Schematic representation of the retinal layers 
Reproduced with permission, Ref (12) 
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Figure 1-6: Schematic representation of the blood retinal barrier.  
Reproduced with permission, Ref (10) 
 The neural retina consists of the photoreceptor layer, the outer plexiform layer, the inner 
nuclear layer, inner plexiform layer and the ganglion layer.   The ganglion cell layer consists of 
the rods and the cones. Retinal capillaries are present in the inner nuclear layer and the outer 
plexiform layer. The endothelial cells junctions of retinal capillaries is lined by tight junctions. 
These tight junctions do not allow xenobotics to enter into the retina forming the inner blood 
retinal barrier. Astrocytes are closely associated with tight junctional proteins present on the 
retinal endothelial cells and support their function(11).  
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1.1.6. Sclera 
The cornea and the sclera together form the outer covering of the eyeball. Together they 
help maintain the shape of the eyeball. The sclera is composed of collagen fibers and 
proteoglycans. The scleral thickness varies from the limbus to the equator. It is relatively thick 
near the limbus (0.53 ± 0.14 mm) and thin near the equator (0.39 ± 0.17 mm). Although both 
cornea and the sclera are made up of collagen fibers, sclera is opaque in nature(13).  
1.2. Glaucoma 
 Glaucoma is one of the world’s primary causes of vision loss and is ranked third in the list of 
people’s major fears (after cancer and heart disease)(14). It affects nearly 70 million people 
worldwide, including an estimated 2.2 million Americans. An additional 2 million Americans 
remain undiagnosed. African-Americans over the age of 40 and all adults over the age of 60, 
especially Hispanics, are at a higher risk for the condition(3). In terms of economic impact, 
Glaucoma accounts for over 7 million visits to physicians each year and is estimated to cost the 
U.S. government over $1.5 billion annually (15). 
The term glaucoma encompasses a group of disorders that cause damage to the optic 
nerve involving loss of retinal ganglion cells, leading to vision loss or blindness if left untreated. 
An increase in the intraocular pressure (IOP) is considered to be a significant risk factor in the 
progression of the disease (16, 17). The most common form of glaucoma is primary open-angle 
glaucoma (POAG), in which fluid builds up in the front chamber of the eye(18). The resulting 
increase of pressure within the eye damages the optic nerve leading to a disruption in the 
transmission of visual information to the brain(19).  
A number of therapeutic candidates are currently available that reduce the IOP (20). The 
classes of medicinal agents and their mechanism of action have been depicted in Table 1-1.  
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Table 1-1: Drugs used in the treatment of glaucoma and their mechanism of action. 
 
However, a reduction in IOP is often not enough to prevent or arrest the development or 
progression of glaucoma related optic neuropathy (21, 22). It has been suggested that neuroglial 
cell cytotoxicity in the optic nerve and retina leads to visual field loss in glaucoma (23). 
Neuroglial cell toxicity impairs macroglial glutamate metabolism and causes microglia and 
macroglia to release inflammatory cytokines following ischemia due to compression or vascular 
occlusion. The released glutamate acts on receptors including the NMDA subtype on the retinal 
ganglion cells to induce calcium influx and the release of toxic ROS leading to apoptosis (23).  
 
Drug class Mechanism of action of decreasing IOP 
Prostaglandin analogs (e.g. 
latanoprost and bimatoprost) 
Increases uveoscleral outflow and/or trabecular 
outflow of aqueous humor; 
Beta-adrenergic receptor antagonists 
(timolol, betaxolol 
Decreases aqueous humor production 
Carbonic anyhydrase inhibitors 
(drozolamide) 
Lowers secretion of aqueous humor by inhibiting 
carbonic anhydrase in the ciliary body. 
Alpha2-adrenergic agonists 
(brimonidine) 
Decreases aqueous humor production and 
increases uveo-scleral outflow 
Sympathomimetics (epinephrine) 
Increase outflow of aqueous humor through 
trabecular meshwork and possibly through 
uveoscleral outflow pathway 
Parasympathomimetics (pilocarpine) 
Contraction of the ciliary muscle, tightening the 
trabecular meshwork and allowing increased 
outflow of the aqueous humour 
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The drawback of currently available therapeutic options in the treatment of glaucoma is 
that they do not exert any neuroprotective activity. Moreover, there is a patient population that 
does not respond to the above listed classes of therapeutic agents. Thus, a new class of 
compounds that would not only lower IOP but would also possess neuroprotective action is 
direly needed in the continued fight against glaucoma. One candidate that exhibits a lot of 
promise is ∆9-Tetrahydrocannabinol (23, 24). 
1.3. Δ9-Tetrahydrocannabinol 
 
 
 
 
 
Figure 1-7: Chemical structure of Δ9-Tetrahydrocannabinol 
 
∆9-Tetrahydrocannabinol (THC, Fig. 1-7) is the primary active ingredient of the plant 
Cannabis sativa (marijuana) and is responsible for the majority of the pharmacological effects.  
People have utilized the plant (that includes numerous cannabinoids) since ancient times for 
medicinal purposes as well as for its intoxicating properties.  While marijuana is primarily 
known as an abused drug, there are important pharmacological properties of THC that could be 
directed to specific therapeutic effects, given an appropriate delivery mechanism. To date, the 
clinical applications approved by the Food and Drug Administration (FDA) are for the control of 
nausea and vomiting associated with chemotherapy and for appetite stimulation of AIDS patients 
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suffering from anorexia and wasting syndrome (25, 26). However, THC’s therapeutic potential 
in a host of other medical areas, including glaucoma, has been a subject of intense research. 
In 2005 an ad hoc expert committee report to the National Eye Institute (NEI) and a 
publication from the American Association of Ophthalmology concluded that there was 
insufficient evidence supporting any added advantages of THC over other glaucoma medications 
(27, 28). At the time when these reports had been prepared a systematic investigation into topical 
delivery of THC had not been carried out in the scientific community. In fact, the literature 
reports available (29, 30), suggested that THC did not demonstrate any therapeutic activity when 
topically administered (31, 32). However, we did demonstrate that the more polar derivatives, 
THC hemisuccinate ester prodrugs N-methylglucamine salt, did produce a significant reduction 
in IOP. Unfortunately, this preliminary compound was highly unstable in aqueous solutions and 
caused ocular discomfort, possibly because of the alkaline pH necessary for solubilization (30). 
Because of the inconclusive activity reports following topical application and lack of a clear 
understanding of the mechanism of action (i.e. whether THC acted through the CNS or local 
cannabinoid receptors, CB1 and/or CB2) (33-37), most of the conclusions drawn by the 
committee, with respect to the utility of THC in glaucoma, were based on the administration of 
THC either through inhalation (smoking) or through systemic administration; routes of delivery 
that is associated with the systemic side-effects of THC.   
Over the last few years a significant amount of research, supported by the NEI and other 
funding agencies, has been focused on the pharmacology of cannabinoids and cannabinoid 
receptors expressed on ocular tissues and glaucoma. It has now been established that CB1 and 
CB2 receptors are expressed on the trabecular meshwork (TM) of the eye and on the retinal 
ganglion cells (38-42). Moreover, studies have demonstrated that the endocannabinoids, THC 
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and a synthetic analog WIN 55-212-2, can bind to the CB1 and CB2 receptors expressed on the 
TM and lead to increased aqueous humor outflow (38-45). The mechanism of action appears to 
be changes induced in the actin cytoskeleton of the TM as a result of activation of the MAPK 
pathway with the binding of cannabinoids to the CB1 and CB2 receptors expressed on the TM. 
This leads to increased drainage of aqueous humor through the TM and a resultant drop in the 
IOP (42-44, 46-48).  
What makes THC particularly attractive is its neuroprotective action. El-Remessy et al. 
demonstrated the effectiveness of THC in NMDA induced retinal neurotoxicity (23). In these 
experiments THC was injected intravitreally. Other reports also demonstrate the effectiveness of 
THC in the preservation of the retinal ganglionic cells (24, 49).  
Thus, there is now little doubt about the potential of THC in the treatment of glaucoma 
and preservation of vision. The challenge lies in the effective and efficient delivery of THC to 
the anterior and posterior chamber ocular tissues through topical THC instillation. So far, this has 
not been examined in a methodical manner. The renewed interest in THC for the treatment of 
glaucoma has produced exciting new evidence and motivated us to reinvestigate topical delivery 
of THC by developing more stable and water soluble THC derivatives. 
1.4. Challenges in topical delivery of THC 
Delivery of THC to the deep seated ocular tissues (TM and retinal ganglion cells) through 
topical administration is a challenging task. THC is an extremely lipophilic compound with a 
high logP value.  Although THC is reported to be absorbed across the intestinal membranes, the 
cornea is very different since it is comprised of a lipophilic epithelium, a hydrophilic stroma 
(90% water) and a lipophilic endothelium. For efficient transcorneal permeation, the therapeutic 
agents need to possess optimum physicochemical characteristics suited for this complex 
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structure. Moreover, there are a host of physiological barriers that minimize penetration of 
topically applied agents to the back-of-the eye. 
Early trials in 1977 examined the use of various oils for topical THC application. 
Amongst these, light mineral oil (LMO) was found to be the most effective. A 0.1% (50 μg in 50 
μL) THC solution in LMO produced an aqueous humor concentration of 0.05 μg/mL which 
correlated to a 6-20% drop in IOP in rabbits (50). Green et al. conducted a study examining the 
effectiveness of a single drop of 0.1% THC (in LMO) in humans. In this study a decrease in IOP 
was not observed in the normal human volunteers (31). Studies conducted (29, 30), with THC 
dissolved in various oily vehicles and topically applied, also did not demonstrate any reduction 
in IOP in the rabbit model. Subsequently, in the year 2000, Kearse and Green evaluated 
transcorneal permeability of THC, in vitro, from various vehicles including LMO (51). With 
LMO as the vehicle, corneal permeability of THC was only 0.18 x 10
-9
 cm/s, which is extremely 
poor by any standard and could be a reason for the observed lack of any IOP lowering effect in 
vivo. Amongst the multiple vehicles tested by Green, maximum permeability (2.4 x 10
-6
 cm/s) 
was observed when hyaluronic acid (0.5%) was present in the formulation. Incidentally, when 
the authors used 30% HPβCD in the vehicle, transcorneal THC permeability was observed to be 
only 0.33 x 10
-9
 cm/s. In 1992, Muchtar et al. demonstrated that a 0.4% THC in a submicron 
emulsion formulation produced intense and long lasting reduction in IOP in a rabbit model of 
ocular hypertension (chymotrypsin treated) (52). Since in vitro transcorneal permeability of THC 
from the submicron emulsions or THC concentrations generated in the aqueous humor in vivo 
from this vehicle was not determined in the studies conducted by Muchtar et al., it is not possible 
to conclude whether the improved IOP lowering effect was as a result of increased dose (from 
0.1% to 0.4%) or increased transcorneal / trans-scleral permeability. These initial literature 
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reports demonstrates that there is sporadic evidence of the effectiveness of topically applied THC 
in glaucoma and highlights the need for a concentrated effort in developing a proper transcorneal 
and transretinal delivery strategy for this very attractive therapeutic candidate. 
Significant effort has not been made to improve the physicochemical characteristics of 
THC, through prodrug modification, to enhance transcorneal permeability characteristics. Thus, 
we will first design and identify a significantly more polar and stable THC prodrug with 
optimized transcorneal permeability characteristics leading to significant IOP lowering capability 
in vivo in rabbits.  
Ophthalmic formulations are usually formulated at high concentration (1-4 % w/v) to 
overcome the short contact time on the ocular surface. THC, due to its water insoluble nature, is 
particularly difficult to deliver topically to the intraocular tissues. Its high lipophilicity also 
provides a challenge to transcorneal permeability due to hydrophilic stroma sandwiched between 
a lipophilic bilayer.  THC tends to accumulate in the lipophilic epithelium of the cornea and not 
pass through the hydrophilic stroma. This necessitates structural modification of THC to improve 
physicochemical characteristics. 
 
1.5. Prodrugs 
Chemical modification of a therapeutic agent by way of prodrug design has become an 
important drug delivery tool (53-55). This is one of the most widely accepted and successful 
strategies for modifying physicochemical characteristics, aqueous solubility, chemical and 
enzymatic stability of drug candidates through linkage of appropriate promoieties. A significant 
positive aspect of the prodrug approach is that it does not induce any change in the membrane 
16 
 
D 
Lipophilic, poor permeation 
PD 
Increased hydrophilicity, 
Chemical and 
Enzymatic Chemical and 
Enzymatic 
PD 
D 
Chemical and 
Enzymatic 
Tear Fluid Cornea Aqueous Humor 
PD 
D 
structure, fluidity or characteristics. The prodrugs are cleaved in vivo to generate the active drug 
and the harmless promoiety, which is eliminated from the body (Fig. 1-8).  
 
 
 
 
 
 
Figure 1-8: Schematic representation of the utility of the prodrug  concept. Prodrug (PD) 
derivatization of the parent drug THC (D), in combination with the formulation excipients 
improves overall permeability. Transcorneal permeability and bioreversion are illustrated by 
arrows. Line thickness represents the extent and higher or lower rates of permeability.  
 
Earlier studies, evaluating topical THC administration, it was observed that the polar 
derivatives partitioned better across the cornea and produced a significant drop in the IOP(30). 
These initial results support lend direct support to the hypothesis of this application and synthesis 
of more stable and hydrophilic THC prodrugs.  
Cytochrome P 450 (CYP) mediated (primarily CYP 2C9 and CYP 3A4) metabolism of 
THC is well established (56, 57). The cornea is also known to express CYP enzymes, although at 
much lower concentrations than that in the liver (58).  A possible benefit that could be derived 
from THC prodrug approach could be diminished CYP mediated metabolism (59, 60) and thus 
greater THC penetration into the aqueous humor.  
17 
 
THC has an acidic phenolic hydroxyl group (pka 10.6) that does not ionize at 
physiological pH but is amenable to chemical modification.  Attachment of an ionizable group in 
the low pH range would improve aqueous solubility and permeability across the hydrophilic 
stroma.  
1.5.1. Dicarboxylic acid (DCA) ester prodrugs  
DCA’s are commonly used promoieties in prodrug derivatization approaches. In earlier 
studies evaluating the effect of topically administered THC, the water soluble salt (N-
methylglucamine) of THC-HS produced a significant drop in the IOP(30). However, the prodrug 
was observed to degrade rapidly and further studies had not been pursued. The improved 
transmembrane permeability characteristics of THC-HS was also observed with transrectal 
delivery: THC-HS demonstrated significantly higher blood levels compared to the other 
prodrugs tested(61). Two esters, Tetrahydrocannabinol hemisuccinate (THC-HS) and 
Tetrahydrocannabinol Hemiglutarate were synthesized. These prodrugs improved aqueous 
solubility due to presence of ionizing group with a low pka. At low pH values when the prodrugs 
were unionized, they demonstrated an inherent improvement in permeability. At physiological 
pH values the permeability was significantly decreased to values even lower than THC since 
they were completely charged.   
1.5.2. Amino acid prodrugs:  
In the past decade amino acids have taken center stage as promoieties for transporter 
targeted prodrug derivatization of hydrophilic drug molecules (62-68). Some studies exploiting 
this mechanism for circumvention of efflux proteins have also been published (69-72). A few 
studies exploring the use of single amino acid based prodrug derivatization to enhance 
hydrophilicity of lipophilic molecules and improve oral absorption have also been reported (73-
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80). This application proposes to systematically design, synthesize, screen and test a matrix of 
mono- and di- amino acid based THC prodrugs. Literature reports indicate that amino acids with 
an electron donating side chain form ester linkages that are more stable. Valine conjugates have 
thus been observed to form extremely stable prodrugs. On the other hand, polar amino acid based 
THC prodrugs may demonstrate greater solubility. Thus, a combination of THC-AAnonpolar-
AApolar may yield significantly more stable and soluble THC prodrugs.  Besides modulation of 
lipophilicity, addition of a peptide bond has been observed to enhance the stability of the ester 
linkage (65). Thus, decreased lipophilicity, increased solubility and enhanced stability may be 
achieved via this approach. Amino acid-dicarboxylic acid esters demonstrated significant 
improvement in physiochemical parameters. In vivo bioavailability of THC from prodrug 
formulations was compared to formulations of THC that were previously studied to determine in 
vivo bioavailability.  
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CHAPTER 2 AIMS OF THE STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
The goal of the project is to achieve optimal concentrations of Δ9-Tetrahydrocannabinol in the 
iris-ciliary body and in the retina through topical delivery. Δ9-Tetrahydrocannabinol being a 
highly lipophilic drug, a combination of chemical modification and formulation approaches will 
be explored.  An in vitro model for the high throughput screening of Δ9-Tetrahydrocannabinol 
prodrugs and formulations also needs to be developed.   
 
SPECIFIC AIMS: 
1. To develop a high throughput in vitro screening tool for Δ9-Tetrahydrocannabinol 
prodrugs and formulations (Chapter 3).   
2. To screen Δ9-Tetrahydrocannabinol dicarboxylic acid prodrugs for solubility, stability, 
physicochemical properties and in vitro permeability across the cornea (Chapter 4).  
3. To formulate Δ9-Tetrahydrocannabinol dicarboxylic acid prodrug exhibiting good 
solubility and permeability characteristics in micellar formulations and determine in vivo 
bioavailability (Chapter 5).   
4. To screen and formulate amino acid, amino acid- amino acid and amino acid dicarbocylic 
prodrugs of THC and determine in vivo bioavailability (Chapter 6).  
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CHAPTER 3                                                                                    
EVALUATION OF ACTIVE AND PASSIVE TRANSPORT PROCESSES IN 
CORNEAS EXTRACTED FROM PRESERVED RABBIT EYES. 
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3.1. ABSTRACT 
In vitro transcorneal permeability studies are an important screening tool in drug 
development. The objective of this research is to examine the feasibility of using corneas isolated 
from preserved rabbit eyes as a model for permeability evaluation. Eyes from male New Zealand 
White rabbits were used immediately or were stored overnight in PBS or HBSS over wet ice. 
Integrity of isolated corneas was evaluated by measuring the TEER and by determining the 
permeability of paracellular and transcellular markers. Active transport was assessed by 
measuring transcorneal permeability of selected amino acids. Esterase activity was estimated 
using p-nitrophenyl assay. In all cases, corneas from freshly enucleated eyes were compared to 
those isolated from the day-old preserved eyes. Transcellular and paracellular passive diffusion 
was not affected by the storage medium and observed to be similar in the fresh and preserved eye 
models. However, amino acid transporters demonstrated lower functional activity in corneas 
excised from eyes preserved in PBS. Moreover, preserved eyes displayed almost 1.5-fold lower 
esterase activity in the corneal tissue. Thus, corneas isolated from day-old eyes, preserved in 
HBSS, closely mimics freshly excised rabbit corneas in terms of both active and passive 
transport characteristics but possesses slightly reduced enzymatic activity. 
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3.2. INTRODUCTION 
Transcorneal absorptive pathway is the most important route of absorption for drugs 
applied topically to the eye (81). A major challenge for pharmaceutical scientists attempting drug 
delivery to the anterior segment of the eye, however, is overcoming the epithelial tight junction 
barriers (82) and also tailoring the pharmaceutical properties of the compound to meet the 
diffusional restrictions imposed by the unique corneal structure comprising of both hydrophilic 
and lipophilic layers. To exert therapeutic activity, a topically administered agent must 
demonstrate sufficient corneal permeability so as to generate adequate drug concentrations at the 
site of action in the anterior ocular chamber. Thus, in vitro transcorneal permeability studies play 
a critical role in the screening and selection of drug molecules and formulation components 
during the design phase.  
Compared to in vivo experiments, in vitro experiments avoid and isolate confounding 
physiological mechanisms from transmembrane diffusion; are less time consuming; amenable to 
high throughput screening; and are thus preferred. Currently, the most favored model for in vitro 
corneal permeability determinations are freshly excised animal corneas (83).  
Rabbit eyes are physiologically very similar to the human eyes and have been extensively 
used to study corneal permeation of therapeutic moieties and to optimize topical formulations 
before preclinical and clinical testing. Unfortunately, these experiments require sacrificing of 
animals procured specifically for the purpose of in vitro testing and also incur high costs 
associated with the caring for laboratory animals (84). In some cases investigators use corneas 
isolated from rabbits used in other protocols. This practice does reduce the number of animals 
required but leaves the investigators unsure about the number and time of availability of the 
tissues and suffers from a lack of control on parameters such as age and sex. Moreover, the 
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experiments carried out in the original protocol may affect ocular permeability characteristics. It 
would be a significant step towards reducing the number of animals required for research 
purpose if the pressing need to specifically sacrifice rabbits for the purpose of carrying out in 
vitro transcorneal experiments could be eliminated.  
Cell cultures, as in vitro models, have not met with much success with respect to 
projection of corneal permeability rates. This is primarily because of the lack of tight junction 
expression, variability in the expression and polarization of transporter proteins (85) and 
difficulty in accurately mimicking the multi-layered and multi-component corneal structure in 
the currently available cell culture models. The cell lines also exhibit time dependent TEER 
values, have a high cost associated with producing and maintaining the cultures and are 
susceptible to microbial contaminations (86). Becker et al. have compared different epithelial 
cell culture models available as well as corneal constructs for in-vitro drug permeation(87). The 
authors compared Statens Serum Institute Rabbit corneal cells (SIRC), transformed human 
corneal epithelial cells (HCE-T) cell lines as well as commercially available SkinEthic 
reconstituted human corneal epithelium (HCE-S) and Clonetrics cultured human corneal 
epithelium (HCE-C).  The results indicated that SIRC, HCE-S and HCE-T could not differentiate 
between the permeabilities of molecules with different physicochemical properties. Only HCE-C 
remained a viable option but has to be used within 24 hours of receipt from the manufacturer. 
Since 
14
[C] mannitol permeability across HCE-C was not reported a direct comparison cannot be 
made between the corneal tissue and the HCE-C cell line in terms of the paracellular diffusional 
barrier properties. Moreover, the authors did not evaluate the cell culture models with respect to 
molecular expression and functional activity of carrier-mediated systems, which plays a critical 
role in transcorneal diffusion.  
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Alternatively, eyes obtained from local abattoirs have been evaluated for studying 
transcorneal permeability (88-90). Various means to transport the excised eyes from the 
slaughterhouse to the laboratory have been reported. Eyes have been transported directly on ice 
or have been placed in solutions and transported over ice(88-90). In all studies, the eyes were 
used within a couple of hours post isolation and knowledge about the effect of prolonged storage 
is currently lacking. Considering that the abattoirs would sacrifice the animals only once or twice 
a week, an option for preserving the procured eyes overnight in specified solutions, would 
significantly help in the research process as well as bring down the need for sacrificing 
laboratory animals.  Storage may, however, lead to alterations in the corneal epithelial structure 
and protein expression which would impact permeability of drug molecules. To date, the effect 
of the storage conditions and storage solutions on corneal integrity and permeability 
characteristics has not been fully investigated.  
Literature indicates that eyes stored in phosphate buffered saline (PBS) and hanks 
balanced salt solution (HBSS) have been successfully used for the preparation of primary cell 
cultures (27, 28, 91), indicating that corneal cells remain viable in these medium for the duration 
tested. However, for these studies, maintenance of the integrity of the corneal epithelial barriers 
was not important and was thus not tested. Corneas stored in unfavorable media would swell, 
display decreased integrity due to the loss of tight junction proteins and may also demonstrate 
diminished functional activity of transporters expressed on the cornea. As a result studies with 
these tissues may predict erroneous permeability values for the test compounds.   
Incidentally, a lot of research has been focused on developing media for the storage and 
transportation of human corneas. Preserved corneas have been evaluated with respect to 
biological and histological characteristics (92-95). Although corneas are shipped for 
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transplantation in human subjects, the storage / transport solutions available are very expensive 
and the sheer volume required for shipping whole animal globes makes these media even less 
attractive for in vitro corneal permeability studies in the drug development process. Moreover, 
surprisingly, the storage solutions currently used have never been evaluated with respect to the 
preservation of the corneal epithelial barrier and transporter characteristics.  
 In this study, we have evaluated PBS and HBSS, two commonly used cell culture media, 
as storage solutions for whole rabbit eye globes. Mannitol and diazepam have been routinely 
used as markers for passive paracellular and transcellular pathways and were thus selected for 
this study. Additionally, corneal permeability of the hydrophilic nucleoside antiviral agent, 
acyclovir, known to diffuse across the cornea by passive diffusion mechanisms(96) , was also 
studied. Quinidine, a lipophilic compound traversing biological membranes by the transcellular 
route using a combination of passive and active diffusional processes(97), was also included as a 
marker compound. Moreover, the functional activity of the three amino acid transporters 
previously reported on the corneal epithelium: the B
0.+
, ASCT1 and L-type amino acid 
transporters were also tested (98-100). In addition to passive and active transport processes, 
activity of esterase enzymes was also compared since these enzymes regulate bioreversion of 
ester prodrugs in the corneal tissue and, thus, can impact net corneal permeability. It was 
assumed that since the eyes would generally be preserved over wet ice, the metabolic rate would 
be minimal. Thus, addition of nutrients, e.g. essential amino acids, would not be necessary. Also, 
since whole animal globes, rather than isolated corneas, would generally be preserved, no 
osmotic agent such as dextran was added to the medium.    
 
27 
 
3.3. EXPERIMENTAL SECTION 
3.3.1. Materials  
Acyclovir was obtained from Hawkins Inc. (Minneapolis, USA) and quinidine from 
Sigma Chemical Co. (St. Louis, USA). Radiolabelled amino acids were obtained from Moravek 
Biochemicals, Inc. (Califonia, USA) and [
14
C]mannitol and [
3
H]diazepam were from Perkin 
Elmer Life and Analytical Sciences (Boston, USA) respectively. All other solvents and 
chemicals were obtained from Fisher Scientific (Fair Lawn, NJ), and used as such. 
3.3.2. Animals 
Male, albino, New Zealand rabbits weighing between 2 to 2.5 kg were procured from 
Myrtles’ Rabbitry (Thompson Station, TN). Animal experiments conformed to the tenets of 
Association for Research in Vision and Ophthalmology (ARVO) statement on the Use of 
Animals in Ophthalmic and Vision Research. 
 
3.4. METHODS 
3.4.1. Corneal Permeation Studies  
Animals were anesthetized with ketazime/xylazine given intramuscularly and euthanized 
by an excess of pentobarbital injected through the marginal ear vein. Some of the globes so 
obtained were either stored in PBS or HBSS, over wet ice, or were taken for immediate isolation 
of the corneas and further experimentation. Corneas from the preserved globes were isolated 24 
hours after storage initiation. Corneas were excised, following previously published protocols 
(101), with approximately 1 mm scleral portions remaining for ease of mounting. The corneas 
were mounted between standard, 9 mm, side-by-side diffusion cells (PermeGear Inc., Bethlehem, 
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PA) with the epithelial layer facing the donor side. Temperature was maintained at 34
o
C during 
the transport studies with the help of a circulating water bath. Dulbeccos phosphate buffered 
saline (DPBS) was used as the transport medium. Volume of the receiver solution (3.2 mL 
DPBS) was slightly higher than that of the donor solution (3 mL drug solution) to maintain the 
natural curvature of the cornea. Contents of both chambers were stirred continuously. Aliquots, 
200 µL, were withdrawn at appropriate time intervals and immediately replaced with an equal 
volume of DPBS and stored at -80
o
 C until further analysis. Unlabeled samples were analyzed 
using an HPLC system. 
To the radioactive aliquots five milliliters of scintillation cocktail (Scintisafe Econo 2, 
Fisher Scientific, USA) was added and the radioactivity was measured using a Liquid 
Scintillation Analyzer (Perkin Elmer Life and Analytical Sciences, Model TriCarb 2900TR, CT, 
USA). 
3.4.2. Light Microscopy 
            Corneas were stained with hematoxylin-eosin using previously published procedures(87). 
Briefly the corneas were dehydrated in increasing ethanol concentration, embedded in paraffin 
wax and then cut into 4µM sections. These sections were stained with hematoxylin and eosin 
solutions and used for light microscopy.  
3.4.3. Trans-epithelial Electrical Resistance (TEER) 
Ag/AgCl electrodes 2 mm in diameter were shaped in the form of circular rings and 
placed approximately 2 mm from the cornea in both the donor and the receiver compartments and 
the chambers were filled with DPBS solution. The electrical resistance across the corneas was 
measured, every hour for a period of three hours, using an experimental setup consisting of a 
waveform generator and digital multimeter (Agilent Technologies, Santa Clara, CA).  
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3.4.4. Paracellular and Transcellular Permeability 
Tight-junction characteristics was compared using acyclovir (1mM) and [
14
C]mannitol 
(0.5 µCi/ml, specific radioactivity 55 mCi/mM) in DPBS, as paracellular diffusion markers. The 
transcellular permeability markers quinidine (0.5µM), and [
3
H]diazepam (0.5 µCi/ml, specific 
radioactivity 70 mCi/mM) in DPBS, were used to compare the properties of the lipoidal cell 
membrane. The studies compared fresh versus preserved corneas.  
3.4.5. Transport Activity of Amino Acid Transporters 
To compare functional activity of corneal amino acid transporters, transcorneal 
permeability of [
14
C]L-Arginine (specific activity 57 mCi/mM), [
14
C]L-Phenylalanine (specific 
activity 391 mCi/mM) and [
14
C]L-Alanine (specific activity 162 mCi/mM)  was determined in 
both freshly excised and preserved rabbit corneas. L-Arginine and L-phenylalanine are known to 
be transported solely by the ATB
0,+
 and LAT1(98, 99) transporters, respectively. Although 
multiple systems are involved in the transport of L-alanine, it permeates across the rabbit cornea 
primarily through the ASCT1(100) transporter. Procedures as described under corneal 
permeation studies were followed. The donor solutions contained 0.5 µCi/mL of the radioactive 
agents.  
Choline chloride and K2HPO4 were used in equimolar quantities to replace NaCl and 
Na2HPO4, respectively, in the transport medium to study sodium dependency of the transport 
process. 2-Amino-2-norbornanecarboxylic acid (BCH) was used as a specific L-amino acid 
transporter inhibitor.  
3.4.6. Enzymatic (esterase) Activity 
A method described by Armstrong et al. was modified to determine the esterase activity 
in the ocular tissues obtained from fresh and preserved rabbit eyes (102). Eyes were carefully 
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dissected and the isolated tissues were stored at -80
o
C. Aqueous humor and vitreous humor were 
used after centrifugation at 13,000 rpm at 4
o
C for 5 minutes. Cornea, iris-cilliary body and 
retina-choroid were homogenized over an ice bath by using methods described elsewhere (103). 
The protein content of the tissue homogenates was standardized to 1 mg/mL using the method of 
Bradford (104). Total esterase activity was determined spectrophotometrically using p-
nitrophenyl acetate (3 mM) as a substrate. In 3 mL acetone, 54.3 mg p-nitrophenylacetate was 
dissolved and the volume was made up to 100 mL using 10 mM phosphate buffer (pH 7.2) to 
obtain a final concentration of 1mM p-nitrophenylacetate. To 1 mL of this solution, 1.9 mL of 
buffer and 100 µL of the tissue homogenate were added in a quartz cell. The contents were 
mixed by briefly inverting the cell and the kinetics of hydrolysis was evaluated at 348 mµ, using 
a Thermo Scientific GENESYS 6™ UV-Vis spectrophotometer, for 5 mins. For these studies, p-
nitrophenyl acetate in the buffer solution, in the absence of the enzyme, was used as a blank.      
3.4.7. HPLC Analytical Method 
Samples were analyzed using an HPLC system consisting of Waters 717 plus autosampler, 
Waters 2475 Multi λ Fluorescence detector (ex λ 270, em λ 380) and Agilent 2295 integrator. 
Waters C18 Symmetry column, 4.6 × 250 mm, was used. Mobile phase consisted of 15 mM 
phosphate buffer (pH 2.5) containing 1% acetonitrile. Retention times were 10.5 ± 0.2 min for 
ACV, 7.4 ± 0.1min for L-Asp-ACV and 7.5 ± 0.1 min for D-Asp-ACV. 
3.4.8. Data Analysis 
Flux and permeability calculations were performed as previously reported (101, 
105).Briefly,  steady state flux values were calculated from the plot of cumulative amount of 
drug in the receiver phase (Ccum) with respect to time (Eq. 1). Steady flux values were 
normalized to donor concentration (Cd) to calculate drug permeability (Eq. 2).  
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 Flux (J)= dCCum/dt                                                                                                (1) 
 
Permeability (Papp) = Flux /Cd                                                                                                           (2)    
 
 
All experiments were carried out at least in triplicate. Student’s t test for unpaired sample 
was used for statistical analysis. Data obtained for multiple groups was subjected to statistical 
analysis using One Way Analysis of Variance (ANOVA).  Variation between the groups was 
checked using Levenes’ test and significant difference between group means was determined 
using Tukeys HSD test. Results were considered statistically significant if p-value was < 0.05.  
 
3.5. RESULTS 
3.4.3. Light Microscopy 
Hematoxylin-eosin stained cross sections for corneas extracted from ocular globes stored 
in PBS/HBSS did not show any significant difference from the fresh corneas (Fig. 3-1).  
3.4.4. Trans-epithelial Electrical Resistance 
TEER values represented in Fig. 3-2 for corneas from eyes preserved in PBS (4.7 ± 0.3 
KΩ.cm2) and HBSS (4.8 ± 0.25 KΩ.cm2) were slightly lower but not significantly different from 
corneas from freshly isolated eyes (5.2 ± 0.3 KΩ.cm2). The TEER values remained constant 
throughout the three hour duration of the experiment.  
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Figure 3-1: Hematoxylin-eosin stained cross section of rabbit cornea. (A) Freshly excised rabbit 
cornea. (B) Cornea extracted from eyes preserved in PBS over wet ice for 24h. (C)Cornea 
extracted from eyes preserved in HBSS over wet ice for 24 hours. 
 
3.4.5. Paracellular and Transcellular transport:  
Permeability of the paracellular marker [
14
C]mannitol was found to be approximately 
three times higher across corneas preserved in PBS or HBSS compared to freshly excised 
corneas (3.96 ± 1.44 x 10
-6
 cm/sec). Ca
+2
 plays an important role in maintaining the integrity of 
tight junctions (106). Since Ca
+2
 is present in HBSS it was thought that their presence would 
help maintain the integrity of the tight junctions. However, significant difference was not 
A 
C 
B 
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observed (Fig. 3-3) in the permeability of [
14
C]mannitol between eyes preserved in PBS (14.88 ± 
1.69 * 10
-6
 cm/sec) and HBSS (13.6 ± 0.26 x 10
-6
 cm/sec). 
Corneal diffusion of acyclovir (Fig. 3-4), however, was not affected by the storage 
medium. Corneal permeability of acyclovir across corneas from fresh eyes (3.25 ± 0.11 x 10
-6
 
cm/sec) was not significantly different from those stored in PBS (4.01 ± 0.38 x 10
-6
 cm/sec).  
Permeability of the transcellular marker, [
3
H]diazepam, in fresh corneas (2.19 ± 0.4 x 10
-
5 
cm/sec) was not significantly different from corneas extracted from eyes preserved in PBS 
(2.35 ± 0.59 x 10
-5
 cm/sec) or HBSS ( 2.59 ± 0.34 x 10
-5
 cm/sec)(Fig. 3-3). Also permeability of 
quinidine (2.0 ± 0.1 x 10
-5
 cm/sec) was not affected when eyes were preserved in PBS (2.5 ± 0.4 
x 10
-5
 cm/sec) as depicted in Fig. 3-4.   
 
Figure 3-2: Trans-epithelial electrical resistance (TEER) values across freshly excised corneas 
and corneas obtained from eyes preserved in PBS/HBSS over wet ice for 24h. Results are 
depicted as mean ± S.D (n=4). 
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Figure 3-3: Transcorneal permeability of [14C]Mannitol (0.5 µCi/ml) and [3H]Diazepam (0.5 
µCi/ml), across corneas from fresh or preserved (in PBS or HBSS over wet ice for 24h) rabbit 
eyes. Results are depicted as mean ± SD (n=3). * p<0.05 
 
3.4.6. Amino Acid Transporter Activity 
Eyes preserved in PBS and HBSS exhibited functional activity of the amino acid 
transporters. In the case of eyes preserved in PBS, transport of [
14
C]L-Arginine (Fig. 3-5) across 
fresh eyes (6.46 ± 2 x 10
-6
 cm/sec) was not significantly different from those obtained from eyes 
preserved in PBS (6.59 ± 2.2 x 10
-6
 cm/sec) or HBSS (7.06 ± 1.68 x 10
-6
 cm/sec).  [
14
C]L-
Arginine transport was inhibited significantly by the specific L-amino acid transporter inhibitor, 
BCH, in eyes preserved in both PBS and HBSS (Fig.3-6A & B).  
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Figure 3-4: Transcorneal permeability of acyclovir and quinidine across corneas from eyes 
preserved in phosphate buffered saline (PBS) over wet ice for 24h compared with freshly excised 
rabbit corneas. The studies were conducted at 34
o
C. Results are depicted a mean ± SD (n=3). * 
p<0.05 
 
Corneal permeability of [
14
C]phenylalanine (9.89 ± 0.49 x 10
-6 
cm/sec, freshly excised 
corneas) was found to be significantly lower when the eyes were preserved in PBS (6.9 ± 0.54 x 
10
-6 
cm/sec). However, permeability values across the corneas from eyes that were preserved in 
HBSS (9.45 ± 0.67 x 10
-6 
cm/sec) (Fig. 3-5) were not significantly different from the fresh 
corneas. In all cases transport of [
14
C]phenylalanine was significantly inhibited in the presence of 
the inhibitor, BCH (Fig. 3-6A & B).  
Active transport of [
14
C]L-Alanine across corneas that were freshly excised (1.87 ± 0.35 
x 10
-5 
cm/sec) was found to be similar to  those from eyes preserved in PBS (1.57 ± 0.90 x 10
-5 
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cm/sec) or HBSS (1.99 ± 0.15 x 10
-5 
cm/sec)(Fig. 3-5). When the studies were carried out in 
sodium free medium permeability was significantly reduced (Fig. 3-6A & B) in all cases. 
The observed corneal permeability values (from fresh eyes) of the amino acids are about 
2 to 2.5 fold lower than literature reports (98-100). This difference may be attributed to use of a 
different radiolabel (
14
C instead of 
3
H) being used in this study.  
 
Figure 3-5: Transcorneal permeability of [14C]L-Arginine (0.5 µCi/ml), [3H]L-Phenylalanine 
(0.5 µCi/ml) and [14C]L-Alanine (0.5 µCi/ml) across corneas from fresh or preserved (in PBS or 
HBSS over wet ice for 24h) rabbit eyes. Results are depicted as mean ± SD (n=3). * p<0.05 
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A. 
 
 
B. 
 
Figure 3-6: Permeability of [14C]L-Arginine (0.5 µCi/ml), [14C]L-Arginine (0.5 µCi/ml) in  the 
presence of BCH (5mM), [14C]L-Phenylalanine(0.5 µCi/ml), [14C]L-Phenylalanine(0.5 µCi/ml) 
in the presence of BCH (5mM), [14C]L-Alanine (0.5 µCi/ml) and [14C]L-Alanine (0.5 µCi/ml) 
in Na
+
 free medium, across corneas from eyes stored for 24h in A) phosphate buffered saline 
(PBS) and B) hanks balanced salt solution (HBSS) over wet ice, at 34
o
C. Results are depicted as 
mean ± SD (n=3). * p<0.05  
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3.4.7. Enzymatic Activity 
Non-specific esterase activity was assessed using p-nitrophenyl acetate assay protocols. 
Esterase activity in preserved corneas was observed to be about 1.5-fold lower compared to the 
freshly excised corneas. There was, however, no significant difference in the esterase activity of 
corneas obtained from eyes preserved in PBS or HBSS (Table 3-1). Iris-ciliary tissues from eyes 
stored in PBS exhibited an almost 2-fold decrease in the esterase activity. However, esterase 
activity was preserved at normal levels in the iris-ciliary tissues when the eyes were stored in 
HBSS. The other ocular tissues tested did not demonstrate any significant difference between 
fresh or preserved eyes.  
 
Table 3-1: Esterase activity in fresh eyes compared to eyes preserved in PBS/HBSS. 
 
 
 
 Rate of hydrolysis of p-nitrophenol acetate [µM/(min.mg protein)] 
 Fresh Eyes Eyes Preserved in PBS Eyes Preserved in HBSS 
Cornea 2.78 ± 0.19 *1.79 ± 0.11 *1.79 ± 0.11 
Aqueous Humor 2.59 ± 0.19 3.09 ± 0.39 2.78 ± 0.32 
Iris-Ciliary Body 14.01 ± 0.11 *8.46 ± 0.11 13.77 ± 0.11 
Vitreous Humor 4.26 ± 0.19 5.06 ± 0.11 4.63 ± 0.19 
Retina-Choroid 3.33 ± 0.19 4.51 ± 0.11 4.51  ± 0.11 
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 3.6. DISCUSSION 
Drug molecules can permeate across the cornea by passive or active transport 
mechanisms. Passive diffusion across the cornea involves the paracellular or transcellular 
pathway. In transcellular diffusion the drug molecules partition into the lipoidal cell membrane, 
but permeability depends on the molecular size, charge and lipophilicity (2). Paracellular 
diffusion, wherein the drug molecules move through the intercellular spaces, is limited by the 
tight junctions present on the superficial epithelial cells (15). Several carrier systems, including 
the amino acid transporters ASCT1, LAT1 and B
o,+
,
 
 have been reported on the corneal 
epithelium of rabbits (98, 100, 107). These transporters are responsible for nutrient transport, but 
are being frequently targeted for drug delivery across biological barriers (107, 108). Thus, when 
transcorneal permeability of a therapeutic candidate is being evaluated in vitro, it is vital that 
these passive and active transport mechanisms remain unaltered in the model.  
The objective of this study was to examine the utility of corneas isolated from preserved 
rabbit eyes for transcorneal permeability studies and to identify a media which would be 
economical, simple to prepare and would maintain the barrier and transport mechanisms of the 
cornea intact. A lot of work has been carried out in the field of preserving human corneas for 
transplantation. The cornea is either stored in organ culture media at physiological temperatures 
(31-37
o
C) or stored in serum free media at hypothermic temperatures (4
o
C)(109). Organ culture 
media are expensive and calls for complex preparation steps. Moreover, the corneas have to be 
de-swelled in dextran before use. This would be a laborious process for preserving corneas for in 
vitro transport experiments. Hypothermic storage media are commercially available but are 
extremely expensive.  
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Spencer et. al. compared  storage of isolated corneas in balanced salt solution(BSS) to 
McCarey Kaufman (MK) media for a period of four days in the presence or absence of the 
steroid hydrocortisone (110). They reported that there was no significant difference if the eyes 
were stored in BSS or M-K media at 4
o
C. Also there was no significant difference on storage 
even in the presence of hydrocortisone. That study, however, was limited to the examination of 
autolysis using the marker enzyme, acid phosphatase. 
In view of the earlier reports, HBSS was chosen as one of the storage media. Since the 
eyes were to be stored in this study for a relatively short duration (not more than 24 hours), PBS, 
the most common storage medium was also selected. Both HBSS and PBS buffers are easy to 
prepare, very economical and use chemicals readily available in most laboratories.  
Currently, two methods are used to transport corneal tissues. Either the whole eyeball is 
transported in a moist chamber, or, the cornea is isolated in situ and transported in a solution. In 
situ isolation has been reported to be better at preserving the cornea compared to transporting the 
whole eye globes (111). The primary focus in preserving human corneas is to maintain 
endothelial cell viability and to prevent autolytic changes after death which may occur due to 
contact with stagnant aqueous humor. Thus, the cornea needs to be separated from the rest of the 
globe. However, for the purpose of drug permeation experiments the endothelium is a very weak 
barrier. Rather, an intact epithelium is essential for in vitro experiments.  
TEER is an electrophysiological technique to measure the integrity of the paracellular 
pathway (112).  Although the TEER values of corneas excised from preserved eyes were 
observed to be higher compared to fresh corneas, the difference was not statistically significant, 
indicating no change in the epithelial barrier properties. However, TEER values alone cannot be 
used as a measure for assessing structural integrity. Permeability of [
14
C]mannitol, a paracellular 
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marker, was found to be three times higher in corneas from preserved eyes compared to freshly 
excised corneas. However, there was no significant difference in permeability of acyclovir, 
another hydrophilic molecule also known to permeate through the paracellular route (113). The 
slightly lower TEER values and higher mannitol permeability of corneas from preserved eyes, 
compared to fresh corneas, indicates that the tight junctions are disrupted to an extent that small 
linear molecules like mannitol can pass through in greater quantities. A more branched molecular 
structure like acyclovir, however, shows no difference in corneal permeability in all models.   
A significant alteration of the tight junction integrity would also have an impact on the 
permeability of lipophilic molecules which diffuse transcellularly. These lipophilic agents can 
diffuse through the paracellular route to a greater extent than in the presence of intact tight 
junctions.  Lack of any changes in the transcorneal permeation values of the lipophilic, 
transcellular markers, diazepam and quinidine, indicates that the integrity of the junction proteins 
is not significantly disrupted, and permeability of only very small molecules, such as mannitol, is 
affected. Moreover, the observed transcellular permeability values for these lipophilic agents 
were statistically similar in the corneal tissues obtained from both fresh and preserved rabbit 
eyes. 
Transporter targeted prodrugs have been designed to enhance transcorneal permeation of 
the parent moiety using a piggy-banking approach, where the prodrug is translocated by the 
carrier system. In-vitro transport experiments are thus often carried out to determine specific 
transporter involvement in the translocation process of a new therapeutic agent or to optimize a 
transporter targeted prodrug design approach. Preservation of the active transport mechanisms is 
thus essential for accurate permeation predictions or for the purpose of ranking various 
candidates. In this study we evaluated the permeability characteristics of three amino acid 
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transporters reported on the rabbit corneal epithelium. Results indicate that the amino acid 
transporters, LAT1, ASCT1 and B
0,+
, remain functionally active in the corneas extracted from 
the eyes preserved in PBS or HBSS as the presence of BCH or lack of sodium significantly 
decrease the transport of their substrates. However, for corneas extracted from whole globes 
preserved in PBS, the permeability of L-Phenylalanine was significantly lower compared to that 
across corneas from eyes that were freshly excised or were preserved in HBSS. Thus, corneas 
from rabbit eyes stored in HBSS exhibited functional activity of all three amino acid transporters 
at levels similar to that in freshly excised corneas. Both PBS and HBSS are isotonic but HBSS 
has added glucose and metal ions. Thus, even at low temperatures where metabolic activity is 
minimal some form of nutrition needs to be added to the medium for amino acid transporters to 
remain fully functional.  
Esterase activity of corneas from eyes preserved in PBS and HBSS was observed to be 
lower compared to freshly excised cornea. The esterase activity in the other tissues, from eyes 
stored in HBSS, was not significantly different. The lower esterase activity in the cornea, 
compared to other tissues, can probably be explained by the fact that the cornea is exposed to the 
storage conditions (solution and period) to a greater extent in comparison to the other tissues 
which remain relatively protected inside the ocular globe, deriving nutrition from the vitreous 
humor. The reduced enzyme activity may impact bioreversion and thus permeability rates. 
However, considering the extremely rapid enzymatic degradation rates observed with most ester 
prodrugs and the low drug concentrations used in general, the impact of this 1.5-fold reduction in 
enzymatic hydrolysis rate may not be very significant with respect to relative permeability 
evaluation. 
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In conclusion, the results from this study indicates that storage of the extracted whole 
rabbit eye in HBSS, over wet ice, for a period of up to 24 hours, preserves the active and passive 
transport mechanisms in the cornea. Eyes shipped from abattoirs in this manner, within this 
timeframe, would serve as an excellent in vitro model for transcorneal permeation studies and 
would significantly decrease the need for laboratory animal sacrifice. Further studies evaluating 
means to extend the period of storage are currently underway. 
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CHAPTER 4                                                                                                 
EFFECT OF ION-PAIRING ON IN VITRO TRANSCORNEAL 
PERMEABILITY OF A Δ9- TETRAHYDROCANNABINOL PRODRUG: 
POTENTIAL IN GLAUCOMA THERAPY. 
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4.1. ABSTRACT 
 
The aim of the present study was to evaluate and improve the in vitro transcorneal 
permeability characteristics of Δ9-tetrahydrocannabinol (THC) through prodrug derivatization 
and formulation approaches. In vitro corneal permeability of THC and its hemisuccinate (THC-
HS) and hemiglutarate (THC-HG) ester prodrugs and WIN 55-212-2 (WIN), a synthetic 
cannabinoid, was determined using isolated rabbit cornea. The formulations studied included 
hydroxypropyl beta cyclodextrin (HPβCD) or random methylated beta cyclodextrin (RMβCD), 
as well as prodrug/ion-pair complexes with l-arginine or tromethamine.  Corneal permeability of 
WIN was found to be two-fold higher than THC in the presence of HPβCD. THC-HS and THC-
HG exhibited pH dependent permeability. In the presence of HPβCD, at pH 5 (donor solution 
pH), both prodrugs exhibited six-fold higher permeability compared to THC. However, 
permeability of the prodrugs was about three-fold lower than that of THC at pH 7.4. RMβCD, at 
pH 7.4, led to a significant improvement in permeability. Formation of ion-pair complexes 
markedly improved the solubility and permeability of THC-HG (7-fold and 3-fold greater 
permeability compared to THC and WIN, respectively) at pH 7.4. The in vitro results 
demonstrate that the use of an ion-pair complex of THC-HG could be an effective strategy for 
topical delivery of THC.    
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4.2. INTRODUCTION 
In 1971 Hepler and Frank published a report that linked marijuana smoking to a 
significant drop in intraocular pressure (IOP) (114). Due to its implications in the treatment of 
glaucoma, this report stimulated intense research towards identification of the constituents 
responsible for this pharmacological action. It was established that ∆9-tetrahydrocannabinol 
(THC, Fig. 3-1A), a primary active constituent of marijuana, is one of the components 
responsible for the IOP lowering effects (29). During the course of further investigations, a 
reduction in IOP was observed when THC was administered either orally or intravenously but 
not when applied topically (31, 115). This lack of topical activity, although some reports did 
demonstrate that topical delivery of THC significantly lowered IOP (116), led researchers to 
conclude that the IOP lowering mechanism of THC was probably due to its centrally acting 
hypotensive effect and not due to activation of local ocular receptors.  
However, recent studies suggest that THC can lower IOP and act as a neuroprotective 
agent by binding to the cannabinoid receptors expressed in the ocular tissues. In the 1990`s two 
cannabinoid receptors, CB1 and CB2, were identified and cloned (117). THC acts as an agonist 
for both CB1 and CB2 receptors. Affinity values for the CB1 and CB2 receptors are 5.05 and 
3.13 nM respectively (118) while the EC50 values for the CB1 and CB2 receptors are 6 nM and 
0.4 nM, respectively (119). Although the distribution of cannabinoid receptors in the body, since 
their identification, has been largely delineated, only recently have cannabinoid receptors been 
identified in the ocular tissues. CB1 receptors are expressed in the trabecular meshwork, iris, 
ciliary body and the retina (39-41, 46) while CB2 receptors have been found on the retina and 
trabecular meshwork (47). These locally expressed cannabinoid receptors are now believed to be 
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involved in the IOP lowering and neuroprotective activity of a number of endocannabinoid and 
synthetic cannabinoid derivatives.  
There are two major pathways for the drainage of aqueous humor from the anterior ocular 
segment: drainage through the Schlemm’s canal or the uveoscleral route. Activation of the CB1 
receptors in the ciliary muscle, by CB1 receptor agonists, induces contraction of the ciliary 
muscle (120). Contraction of the ciliary muscle leads to widening of the intercellular spaces in 
the trabecular meshwork and enhances outflow of aqueous humor (8). Recently, bimatoprost, a 
prostaglandin analog that enhances uveoscleral outflow, has been shown to contract the human 
ciliary muscle through CB1 mediated mechanism (121). Furthermore, activation of CB1 
receptors leads to fragmentation and reduction of actin stress fibers in the trabecular meshwork, 
further enhancing outflow of aqueous humor (46). That THC can reduce IOP through the local 
CB1/CB2 receptors can also be inferred from a previous clinical study. Merritt et al. 
demonstrated that 0.1% THC in mineral oil when given topically led to a 5.4 mm drop in IOP but 
was accompanied with a 12 mm drop in systolic blood pressure (116). A 10 mm drop in systolic 
blood pressure, following systemic THC administration, should be associated with less than a 1 
mm drop in IOP (122).  Also, 0.05% THC in mineral oil, topically administered, led to a 4.8 mm 
drop in IOP with no systemic hypotensive effect. Thus, these data suggest that topical THC is 
probably acting locally through the ocular cannabinoid receptors to reduce the IOP, and not 
through the systemic pathway.  
In glaucoma, a reduction in IOP is often not enough to prevent or arrest the development 
or progression of glaucoma related optic neuropathy (21, 22). Vision loss continues even after 
significant IOP reduction has been achieved. It has been suggested that neuroglial cell 
cytotoxicity in the optic nerve and retina leads to visual field loss in glaucoma (23). Neuroglial 
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cell toxicity impairs macroglial glutamate metabolism and causes microglia to release 
inflammatory cytokines following ischemia due to compression or vascular occlusion. The 
released glutamate acts on receptors, including the NMDA subtype, on the retinal ganglion cells 
to induce calcium influx and the release of toxic reactive oxygen species, leading to apoptosis 
(23). Recent studies have demonstrated that CB2 or non-specific CB1/CB2 agonists were able to 
protect retinal cells from oxidative stress, but specific CB1 agonists had no effect (123). 
Intravitreally administered THC has been demonstrated to act as a neuroprotective in a rat model 
of glaucoma (23, 24). Hampson et al. also reported that the neuroprotective activity of THC 
could also be independent of CB1 receptor activation (124). Although the mechanism of 
neuroprotection of THC is not yet clearly understood, it could be due to the activation of CB2 
receptors, its antioxidant effect or some other mechanism (124-126). The current evidence 
clearly suggests that THC possesses both IOP lowering and neuroprotectant activity, which are 
independent of each other.  
While significant efforts have been directed towards understanding the pharmacology of 
THC, design of effective topical delivery strategies for THC has not seen much activity. In 1977 
Green et al. published a paper comparing corneal penetration of THC from different oils and 
found that light mineral oil was the best of the four vehicles tested (50). The study reported a 
twenty percent drop in IOP of normotensive rabbits when a 50 µL dose (0.1% w/w THC) was 
administered topically. However plasma drug concentrations were not reported. All further 
pharmacological studies, with THC administered topically, were carried out using light mineral 
oil as the vehicle. However, THC being a highly lipophilic molecule, with an aqueous solubility 
of only 1-2 µg/mL and a logP of 6.3 (127), its effective partitioning from the oily vehicle into the 
tear film would be suspect. Kearse et al. compared in vitro corneal permeability of THC from 
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different vehicles and observed that the permeability of THC from light mineral oil was only 
1.86 X 10
-8
 cm/s (51). Thus, the lack of topical activity observed in the earlier in vivo reports 
could be due to the ineffective delivery of THC to the target ocular tissues rather than absence of 
local pharmacological activity. When higher doses were administered, to increase the amount of 
THC permeating across the cornea, systemic side effects were observed. Thus, development of a 
formulation that can effectively deliver THC across the cornea is needed prior to its evaluation 
for therapeutic activity. 
The aim of the current project was to improve the aqueous solubility and in vitro 
permeability of THC employing complex formation and prodrug derivatization strategies. 
Dicarboxylic acid esters are commonly used promoieties in prodrug derivatization approaches. 
These ester prodrugs exhibit higher aqueous solubility since they are ionized at physiological pH 
values. The hemisuccinate ester (THC-HS, Fig. 3-1B) and hemiglutarate ester (THC-HG, Fig. 3-
1C) prodrugs were synthesized and evaluated for transcorneal permeability. The effect of 
cyclodextrins and counterion adduct/complex formation on the solubility and corneal 
permeability of THC and/or the two prodrugs were studied.  
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Table 4-1: Chemical structures of A) Δ9-Tetrahydrocannabinol (THC), B) Δ9-
Tetrahydrocannbinol Hemisuccinate (THC-HS) and C) Δ9-Tetrahydrocannbinol Hemiglutarate 
(THC-HG) D) WIN 55-212-2 (WIN). 
 
4.3. EXPERIMENTAL SECTION 
4.3.1 Chemicals 
Hydroxypropyl beta cyclodextrin (HPβCD), randomly methylated beta cyclodextrin 
(RMβCD), 2-aminobicyclo-[2,2,1]-heptane-2-carboxylic-acid (BCH), l-arginine and Sigmacote® 
were obtained from Sigma (St. Louis, MO). WIN-55-212-2 (WIN) was purchased from Tocris 
Bioscience (Ellisville, MO). All other chemicals were obtained from Fisher Scientific (St. Louis, 
MO). All solvents used for analysis were of HPLC grade.   
4.3.2. Animal Tissues 
 Whole eye globes of albino New Zealand White rabbits were obtained from Pel Freez 
Biologicals (Rogers, AR). Eyes were shipped overnight in Hanks balanced salt solution over wet 
ice and used immediately on receipt.  
4.4. METHODS 
4.4.1. Preparation of Dicarboxylic acid ester prodrugs 
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Dicarboxylic acid prodrugs (THC-HS and THC-HG) were synthesized and characterized 
according to previously published procedures (128). 
4.4.2. Solubility of the Prodrugs 
4.4.2.1. Solubility in Buffers: Since THC binds to plastic, all experiments were carried out in 
plastic vials/tubes coated with Sigmacote
®
 or borosilicate glass vials were used (129). Specific 
measured quantities of stock solutions of THC-HS or THC-HG were transferred to the 
borosilicate glass or coated plastic vials and the organic solvent was evaporated using a stream of 
nitrogen gas. Dulbecco’s Phosphate Buffered Saline (DPBS) or Isotonic Phosphate Buffered 
Saline (IPBS) was then added to the vials and the resulting mixture was sonicated for 10 min to 
dislodge the drug sticking to container walls and allowed to equilibrate for 24 hours at 25 °C in a 
shaking water bath at 75 shakes per minute. The resulting suspension was centrifuged at 16000 x 
g in a Fisher Scientific acuSpin micro17R centrifuge for 10 min using silicon coated centrifuge 
tubes. The supernatant was collected and analyzed by HPLC.  
4.4.2.2. Solubility in Cyclodextrins:  Solubility of THC-HS and THC-HG in a 2.5% solution of 
HPβCD or RMβCD in DPBS or IPBS was determined using methods described under solubility 
of THC-HS/THC-HG in buffer solutions.  
4.4.2.3. Solubility in Presence of l-arginine/tromethamine: Formation of an ion-pair complex 
with a hydrophilic counter ion could lead to an improvement in the solubility of the drug. 
Aliquots of stock solutions of THC-HS and THC-HG were transferred to glass vials and the 
organic solvent was evaporated using a stream of nitrogen gas. l-arginine or tromethamine in 
IPBS was then added to reach specific concentrations of the prodrug and the counterion. The 
prodrug THC-HS/THC-HG and the counterion l-arginine/tromethamine were added in increasing 
concentrations, keeping the ratio of drug:counterion constant (1:2). The combinations were then 
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processed for solubility determination following the same methods as described under solubility 
of the prodrugs in buffer solutions.    
4.4.3. In Vitro Transcorneal Permeability Studies 
Excess THC, THC-HS, THC-HG and WIN were equilibrated in DPBS containing 2.5% 
HPβCD or RMβCD (pH adjusted to 5, 6 and 7.4) for 24 hours at 25 °C in a shaking water bath. 
The supernatant containing the drug-cyclodextrin complex was used in the transport studies. 
Donor solutions were analyzed for drug content at the beginning and after completion of the in 
vitro permeability studies.  Receiver solution for all permeability studies with cyclodextrin 
formulations consisted of 2.5% HPβCD solution in DPBS with pH adjusted to 7.4.  
Transcorneal permeability of the ion-pair complexes of THC-HG with l-arginine (THC-
HG-ARG) and tromethamine (THC-HG-TRIS) was also studied. THC-HG (1 mM) was 
equilibrated with l-arginine (2 mM) or tromethamine (2 mM) in IPBS at 25 °C for 24 hours in a 
shaking water bath. The supernatants were collected, analyzed and used as the donor solution. 
For the studies investigating permeability of the ion-pair formulations, receiver medium 
consisted of 2.5% HPβCD solution in IPBS with pH adjusted to 7.4.  
Eyes were used immediately upon receipt. Corneas were excised, following previously 
published protocols(101). Briefly an incision was made about 2 mm from the corneal-scleral 
junction and the cornea was excised by cutting radially along the sclera. The 2 mm scleral 
portions help in easy mounting of the cornea. The excised corneas were immediately mounted 
between standard, 9 mm, side-by-side diffusion cells (PermeGear Inc., Hellertown, PA). The 
half-cell facing the epithelial layer was termed as the donor compartment. A circulating water 
bath was used to maintain the temperature at 34 °C during the transport studies. The volume of 
the receiver solution (3.2 mL) was maintained slightly higher than that of the donor solution (3 
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mL drug solution) to maintain the natural curvature of the cornea. Both chambers were stirred 
continuously using magnetic stirrers. Aliquots, 600 µL, were withdrawn every thirty minutes for 
three hours and immediately replaced with an equal volume of the receiver solution. Samples 
were analyzed following the method described in the analytical methods section.  
4.4.3.1 Involvement of Amino Acid Transporter 
Amino acid transporters have been identified on the rabbit/human cornea and are 
functionally active. l-arginine is a substrate for amino acid transporter B
0,+
, a sodium and energy 
dependent transporter and is specifically inhibited by BCH. The THC-HG/l-arginine adduct 
could be conveyed across the cornea by B
0,+
. Permeability of THC-HG/l-arginine complex was 
thus determined in the presence of 5 mM BCH to evaluate involvement of B
0,+ 
in the transport 
process.  
4.4.4. Stability in Ocular Tissue Homogenates  
4.4.4.1. Tissue Preparation: Aqueous and vitreous humor was used as such and without any 
dilution. They were centrifuged at 16000 x g for 10 min at 4 ºC and the supernatant was used. 
Other ocular tissues used in this study were homogenized in ice cold DPBS, on an ice bath, using 
TISSUEMISER (Fisher Scientific, St Louis, USA). The homogenate was then centrifuged at 
16000 x g at 4 °C for 15 min.  Protein content in the supernatant was determined according to the 
method of Bradford (101) and was standardized to 1 mg/mL.    
4.4.4.2. Hydrolysis Procedure: The standardized homogenates were equilibrated for 30 min at 
37 °C to activate the enzymes. To 1.98 mL of the supernatant, 20 µL of THC-HG (1 mg/mL) in 
ethanol was added and mixed. Samples were withdrawn at predetermined time intervals. Bio-
conversion of THC-HG/l-arginine and THC-HG/tromethamine complex to THC in aqueous 
humor was also evaluated. To 0.95 mL of aqueous humor 50 µL of THC-HG-ARG or THC-HG-
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TRIS complex (1:2) were added. Samples, 200 µL, were withdrawn at specific time intervals. An 
equal volume of ice cold methanol was added to the aliquoted samples, to arrest the reaction, and 
centrifuged at 16000 x g for 10 min. The supernatant was collected and taken for analysis.  
4.4.5. Analytical Method 
Samples were analyzed using a Waters high pressure liquid chromatography system 
consisting of Waters 600 pump controller, refrigerated Waters 717 plus autosampler, Waters 
2487 UV detector and Agilent 3395 integrator. Primary stock solutions of THC, THC-HS and 
THC-HG were prepared in hexane and stored at -15 °C. For the preparation of standards a 
known amount of stock was taken and hexane was evaporated using nitrogen gas. Standards 
were reconstituted using mobile phase. Mobile phase consisted of a 85:15 mixture of methanol 
and 0.84 % v/v glacial acetic acid. A Phenomenex Luna PFP (2), 4.6 x 250 mm column was 
used. Analytes were detected at 226 nm. For quantification of THC, THC-HS and THC-HG a 
standard curve was constructed with a linear range of 0.1 to 5 µg/mL. Injection volume was 100 
µL. Samples from the permeation studies were injected as such while the solubility study 
samples were diluted appropriately, in mobile phase, before being injected. The standard curve 
generated had co-efficient of determination values (r
2
) greater than 0.9999. Retention times for 
the analytes were as follows: THC (10.1 min), THC-HS (13 min) and THC-HG (14.3 min). 
Limit of detection and quantifications were 5 ng/mL and 50 ng/mL, respectively. 
4.4.6. Data Analysis    
Flux was calculated from the plot of cumulative amount of drug (Dcum) in the receiver 
phase with respect to time (Eq. 1). Flux values were normalized to donor concentration (Cd) to 
calculate drug permeability (Eq. 2).  
Flux (J)= dDCum/dt                                                                                             (1) 
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Permeability (P) = Flux /Cd                                                                                                           (2)    
 
All experiments were carried out atleast in triplicate. Data obtained was subjected to 
statistical analysis using ANOVA. Variance between the groups was checked using Levenes’ 
test. Statistical difference between groups was checked using Tukeys HSD. A p-value ≤ 0.05 was 
considered to signify statistically significant difference.  
Table 4-2: Solubility of THC-HS and THC-HG in IPBS and DPBS as such or IPBS and DPBS 
containing 2.5% HPβCD or RMβCD at 25 ⁰C. Results are depicted as mean ± SD (n=3). 
 
Prodrug Buffer 
Cyclodextrin 
(2.5%) 
Solubility (µg/mL) 
THC-HS 
IPBS 
- 9.8 ± 0.9 
HPβCD 144.9 ± 23.4 
RMβCD 197.5 ± 57.9 
DPBS 
- 5.4 ± 0.3 
HPβCD 418.9 ± 13.8 
RMβCD 430.2 ± 75.2   
THC-HG 
IPBS 
- 18.8 ± 3.1 
HPβCD 899.9 ±  27.5 
RMβCD 857.7 ± 49.4 
DPBS 
- 4.3 ± 0.2 
HPβCD 678.5 ± 84.2 
RMβCD 910.6 ± 62.8 
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4.5. RESULTS 
4.5.1. Solubility 
4.5.1.1. Solubility in Buffers: Solubility of the prodrugs, THC-HS and THC-HG, in IPBS or 
DPBS (Table 4-1) was found to be markedly higher than the reported solubility of THC (1-2 
µg/mL) in water (127). THC-HS and THC-HG demonstrated significantly higher solubility in 
IPBS (9.8 ± 0.9 and 18.8 ± 3.1 µg/mL, respectively) compared to that in DPBS (5.4 ± 0.3 and 4.3 
± 0.2 µg/mL, respectively).      
 
Table 4-3: Solubility of THC-HG in IPBS, and the resulting solution pH, as a function of 
increasing concentrations of THC-HG and l-arginine/tromethamine while maintaining the ratio 
of drug: counter-ion constant (1:2), at 25 ⁰C. Results are depicted as mean ± SD 
 
4.5.1.2. Solubility in Cyclodextrins: Solubility of the prodrugs (THC-HS and THC-HG) was 
significantly improved in the presence of cyclodextrins (Table 4-1). A significant difference 
between the solubility of THC-HS in the presence of HPβCD (144.9 ± 23.4 µg/mL) and RMβCD 
(197.5 ± 57.9 µg/mL) was not observed in IPBS. With both HPβCD (418.9 ± 13.8 µg/mL) and 
RMβCD (430.2 ± 75.2 µg/mL), THC-HS demonstrated a 2-fold higher solubility in DBPS 
Counter ion 
THC-HG 
(mM) 
Counter Ion 
(mM) 
pH 
Concentration of THC-
HG in solution (µg/mL) 
l-Arginine 
1 2 7.4 423.4 ± 52.2 
2 4 7.9 795.5 ± 51.1 
3 6 8.4 1154.9 ± 47.5 
4 8 8.9 1716.5 ± 49.1 
Tromethamine 
1 2 7.5 219.3 ± 16.9 
2 4 7.6 517.2 ± 46.5 
3 6 7.7 868.5 ± 80.5 
4 8 7.8 1158.4 ± 39.9 
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compared to that in IPBS. THC-HG solubility in the presence of the cyclodextrins was about 1.5-
2 fold higher compared to THC-HS in DPBS containing HPβCD or RMβCD. Solubility of THC-
HG in IPBS was independent of the cyclodextrin used. However in DPBS higher solubility in 
RMβCD was observed compared to HPβCD (Table 4-1). 
4.5.1.3. Solubility in Presence of l-arginine/tromethamine: Since THC-HS and THC-HG 
demonstrated higher aqueous solubility in IPBS compared to DPBS (Table 4-1), ion- pairing 
studies with l-arginine and tromethamine were carried out in IPBS only. Preliminary studies 
demonstrated that THC-HS was unstable in the presence of l-arginine and tromethamine in IPBS. 
At the end of the 24 hour equilibration period, THC-HS was completely converted into THC 
(data not presented). Solubility of THC-HG in IPBS was found to increase linearly with 
increasing concentrations of l-arginine or tromethamine (Table 4-2). At the highest concentration 
studied, the solubility of THC-HG (4 mM) with l-arginine (8 mM) was found to be 1716.5 ± 49.5 
µg/mL. Aqueous solubility of THC-HG (4 mM) with tromethamine (8 mM) was found to be 
1158.4 ± 39.9 µg/mL. With a further increase in the concentrations of l-arginine or tromethamine 
the solution pH was observed to increase above pH 10 and were not investigated any further.  
4.5.2. Corneal Permeation 
Transcorneal permeability of THC (0.15 mM) across isolated rabbit cornea at pH 7.4 was found 
to be 5.57 x 10
-6
 cm/s (Fig. 3-2). DPBS containing 2.5% HPβCD was used to prepare the donor 
solution. Decrease in donor solution pH to 5 did not produce any significant effect on the corneal 
permeability of THC. When the concentration of HPβCD in the donor solution was increased 
from 2.5% to 30%, keeping the drug concentration constant, THC permeating into the receiver 
chamber was found to be below the detection limit (<0.05 µg/mL). WIN, a synthetic CB1/CB2  
agonist, which has been demonstrated to reduce IOP when applied topically, exhibited 2-fold
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Table 4-4: Donor concentrations and flux of THC, THC-HS and THC-HG (in terms of total 
THC) and WIN in different vehicles at 34 °C across isolated rabbit cornea. Results are depicted 
as mean ± SD (n=3). 
 
*Maximum flux values were calculated theoretically by multiplying observed permeability with 
maximum solubility values depicted in Table 4-1 and Table 4-2. Maximum values have not been 
presented for formulations wherein maximum solubility was not calculated. 
Drug 
Donor 
pH 
Donor Vehicle 
Donor 
Concentration 
(µg/mL) 
Flux 
(µg/cm2/min x 
10-2) 
Predicted Maximum 
Flux*  (µg/cm2/min x 
10-2) 
THC 
5 2.5 % HPβCD in DPBS 40.7 ± 0.7 1.7 ± 0.2 - 
7.4 2.5 % HPβCD in DPBS 46.8 ± 2.9 1.6 ± 0.1 - 
7.4 30 % HPβCD in DPBS 40.1 ± 0.7 
No drug 
detected 
- 
7.4 2.5 % RMβCD in DPBS 19.9 ± 0.9 1.5 ± 0.2 - 
WIN 
5 2.5 % HPβCD in DPBS 73.3 ± 2.8 5.4 ± 0.3 - 
7.4 2.5 % HPβCD in DPBS 86.3 ± 12.4 5.7 ± 0.6 - 
7.4 30 % HPβCD in DPBS 97.2 ± 0.4 0.8 ± 0.1 - 
7.4 2.5 % RMβCD in DPBS 238.3 ± 17.5 13.2 ± 0.6 - 
THC-HS 
5 2.5 % HPβCD in DPBS 64.3 ± 4.3 14.9 ± 0.9 - 
6 2.5 % HPβCD in DPBS 29.8 ± 2.9 1.5 ± 0.1 - 
7.4 2.5 % HPβCD in DPBS 73.1 ± 0.7 0.9 ± 0.5 5.1 ± 3.7 
7.4 2.5 % RMβCD in DPBS 103.5 ± 12.9 3.5 ± 0.1 14.7 ± 0.5 
THC-HG 
5 2.5 % HPβCD in DPBS 53.8 ± 3.1 11.4 ± 1.1 - 
6 2.5 % HPβCD in DPBS 30.1 ± 1.5 1.7 ± 0.2 - 
7.4 2.5 % HPβCD in DPBS 30.9 ± 1.9 0.3 ± 0.1 6.5 ± 2.1 
7.4 2.5 % RMβCD in DPBS 30.1 ± 0.4 1.9 ± 0.2 56.3 ± 6.1 
7.6 2 mM l-arginine in IPBS 78.9 ± 8.1 14.9 ± 0.9 79.9 ± 11.9 
7.6 2 mM l-arginine + BCH in IPBS 71.6 ± 6.5 13.4 + 0.9 - 
7.6 2 mM Tromethamine in IPBS 71.9 ± 2.2 17.1 ± 2.6 51.9 ± 9.1 
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higher corneal permeability compared to THC. Permeability of WIN across the cornea, like 
THC, was also found to be pH independent. When the concentration of HPβCD in the donor 
solution was increased from 2.5% to 30%, keeping the concentration of WIN constant, a 10-fold 
decrease in corneal permeability of WIN was observed. Replacing HPβCD with RMβCD (2.5%) 
in the donor solution led to a 2-fold improvement in the in vitro corneal permeability of THC but 
did not affect the permeability of WIN. Expectedly, THC-HS and THC-HG demonstrated pH 
dependent permeability across the cornea. At pH 5 (donor solution pH) permeability of THC-HS 
and THC-HG was about 6-fold higher compared to the permeability of THC in 2.5% HPβCD in 
DPBS (Fig. 3-3).  An increase in the donor solution pH significantly decreased the permeability 
of THC-HS and THC-HG. Compared to the permeability of THC in 2.5% HPβCD (pH 7.4), 
permeability of THC-HS and THC-HG was about 2-fold higher at pH 6 and about three fold 
lower at pH 7.4 (Fig. 3-3). This is probably because the prodrugs are ionized at physiological pH 
values (pKa of THC-HG is 3.6 ± 0.4). For all permeability studies involving cyclodextrin 
formulations, DPBS containing 2.5% HPβCD was used as the receiver solution.   
To shield the negative charge on the prodrugs, permeability of THC-HS and THC-HG 
was evaluated in the presence of l-arginine and tromethamine since they are positively charged at 
physiological pH values. At physiological pH (pH 7.4) THC-HG-ARG and THC-HG-TRIS were 
found to be almost 7-fold more permeable compared to the permeability of THC in 2.5 % 
HPβCD. This was about 3-fold higher compared to the corneal permeability of WIN at pH 7.4. 
IPBS containing 2.5% HPβCD was used as the receiver solution in these studies for determining 
the permeability of the ion-pairs. Donor concentrations (in terms of THC) and flux values for all 
the formulations have been reported in Table 4-3.   
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Analysis of the donor solution samples collected at the start and end of the permeation 
studies indicated that THC-HS and THC-HG, in all formulations studied, remained intact for the 
duration of the in vitro permeability studies.  
 
Figure 4-1: Permeability of THC and WIN at 34 °C across isolated rabbit cornea. The legends 
indicate the donor solution pH and composition.  Receiver solution used in these studies was 
DPBS containing 2.5% HPβCD (pH 7.4). Results are depicted as a mean ± SD (n=3). *p < 0.05.  
†
ND – THC concentrations could not be detected in the presence of 30% HPβCD.   
4.5.2.1. Involvement of amino acid transporter   
BCH is an L-amino acid transporter inhibitor. There was no significant difference in the 
permeability of the THC-HG-ARG complex in the presence of 5 mM BCH.  
4.5.3. Stability in corneal homogenates 
Apparent first order enzyme mediated degradation rate constants (after adjusting for 
buffer mediated hydrolysis) and half-life of THC-HG in aqueous humor, vitreous humor and 
other ocular tissue homogenates (1 mg/mL) have been depicted in Table 4-4. THC-HG was 
rapidly converted to THC in the aqueous humor (t1/2, 25 ± 2.1 min) and the retina choroid (t1/2, 
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36.7 ± 1.2 min). Bio-conversion of THC-HG in aqueous humor was not affected by the presence 
of l-arginine or tromethamine.   
 
 
Figure 4-2: Permeability of THC-HS and THC-HG (in terms of total THC) at 34 °C across 
isolated cornea. The legends indicate the donor solution pH and composition. Receiver solution 
used in these studies was DPBS containing 2.5% HPβCD (pH 7.4). Results are depicted as a 
mean ± SD (n=3). *p < 0.05.  
 
4.6. DISCUSSION 
Establishing effective delivery of a drug to the target tissues is a prerequisite to clinical 
studies evaluating pharmacological response. However, all previous clinical studies evaluating 
topical effectiveness of THC in glaucoma used light mineral oil based formulations, a vehicle 
from which in vitro corneal permeability of THC is reported to be 1.86 x 10
-8
 cm/s (51). Thus, 
inefficient delivery of THC to the target ocular tissues could be responsible for the sporadic 
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evidence with respect to the efficacy of topically administered THC on IOP.  In the present 
investigation, prodrug and formulation approaches to improve the aqueous solubility and 
transcorneal permeability of THC were studied.  
 
 
Figure 4-3: Comparative permeability (in terms of total THC) of THC, WIN, THC-HG-ARG 
complex, THC-HG-ARG complex + BCH and THC-HG-TRIS complex at 34 °C across isolated 
rabbit corneas. The legends indicate the donor solution pH and composition. Receiver medium 
was 2.5 % HPβCD in DPBS (pH 7.4) for THC and WIN, while for the ion-pair complexes the 
receiver solution was IPBS containing 2.5% HPβCD (pH 7.4). Results are depicted as a mean ± 
SD (n=3). *p < 0.05.   
Cyclodextrins have been widely used as complex forming agents to improve the 
solubility and permeability of many hydrophobic drug candidates (130). Since their discovery, 
cyclodextrins have been used in numerous marketed products. Of these, HPβCD when used up to 
12.5% w/v has been shown to be safe and well tolerated when administered topically to the eye 
(131). It has also been demonstrated that HPβCD only transports the drug molecule to the surface 
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of the membrane and does not itself permeate through the membrane in any significant quantities 
(131). 
 
Figure 4-4: Cumulative transport of THC, THC-HS and THC-HG (in terms of total THC) from 
cyclodextrin and ion-pair based formulations across isolated rabbit corneas at 34 °C, as a 
function of time. The donor solution (Don) and receiver medium (Rec) pH and composition is 
indicated in the legends. Results are depicted as a mean ± SD (n=3). *p < 0.05.   
 
RMβCD has also been used by researchers in ophthalmic drug delivery (132). When used 
at high concentrations both HPβCD and RMβCD have been shown to affect tight junction 
integrity (133, 134). However, in vitro corneal permeability studies demonstrate that use of 
HPβCD up to concentrations of 5 % w/v does not affect the tight junctions (134). Concentration 
dependent effect of RMβCD on corneal tight junctions has not been reported as yet. Thus, some 
of the observed enhancement in corneal permeability in the presence of the cyclodextrins could 
have resulted from the interaction of the cyclodextrins with the corneal tight-junctions also, 
besides enhanced solubility and greater availability of the drug at the corneal surface.  
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Permeability of THC from 2.5% HPβCD solutions in DPBS was found to be about 300- 
fold higher compared to the permeability of THC from light mineral oil based formulations. 
Incidentally, when Keith and Green used 30% HPβCD as the vehicle, transcorneal permeability 
of THC was observed to be only 3.3 x 10
-8
 cm/s (51). Thus, permeability of THC from the 2.5% 
HPβCD  drug saturated solution in this study was about 200 times higher compared to the 
permeability value reported by Green et al.(51). 
 
Table 4-5: Apparent first order rate constants (k*) and half-lives (t1/2) of THC-HG in ocular 
tissue homogenates.  Results are depicted as mean ± SD (n=3). 
 
Consistent with this observation, when the concentration of cyclodextrin was increased to 
30%, from 2.5% in the current study, while keeping the drug concentration constant, a dramatic 
decrease in corneal permeability was observed (Fig. 4-2). Our results thus demonstrate that the 
presence of excess amounts of free cyclodextrins (use of unsaturated drug cyclodextrin solutions) 
results in decreased permeability. WIN also demonstrated a similar phenomenon (Fig. 4-2). 
Thus, the presence of excess cyclodextrin probably leads to a decrease in the free drug 
concentration available for permeation. Interestingly, the use of RMβCD improved permeability 
of THC by almost 2-fold. However, even after such dramatic improvements, corneal 
permeability of THC only equaled the permeability of WIN, which is about five times more 
 
 Cornea 
Aqueous 
Humor 
Iris-Ciliary 
Body 
Vitreous 
Humor 
Retina Choroid 
THC-
HG 
k
*
x 10
3 
(min
-1
) 
 9.7 ± 0.6    28.1± 0.1 14.7 ± 1.9      4.8 ± 0.2 18.9 ± 0.7 
t1/2 
(min) 
 71 ± 1.2  25 ± 2.1 47.5 ± 5.1 144.7 ± 5.3 36.7 ± 1.2 
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potent than THC. Thus, the relatively hydrophilic THC-HS and THC-HG prodrugs were 
evaluated as a means to further improve transcorneal permeability.  
Aqueous solubilities of THC-HS and THC-HG were found to be significantly higher in 
IPBS than in DPBS (Table 4-1). This could be due to the higher ionic strength of DPBS, 
compared to IPBS, which could inhibit ionization of the prodrugs and thus aqueous solubility. 
Use of cyclodextrins significantly improved the aqueous solubility of THC-HS and THC-HG in 
both IPBS and DPBS (Table 4-1).  However, aqueous solubility of THC-HS in HPβCD or 
RMβCD in DPBS was found to be higher than that in IPBS. The increased solubility in DBPS 
could be due to the presence of higher concentrations of unionized THC-HS in DPBS which may 
demonstrate higher affinity for the cyclodextrins. Alternatively, stability of THC-HS in DPBS 
could be higher compared to that in IPBS resulting in higher solubility. Generally, THC-HG 
demonstrated higher solubility compared to THC-HS. This is probably because THC-HG is 
significantly more stable than THC-HS, especially at higher pH values. The solubility studies 
involved a 24 hour equilibration period and would thus be exposed to significant hydrolysis 
(128). 
THC-HS and THC-HG demonstrated pH dependent corneal permeability. At pH 5 (donor 
solution pH) the permeability of the prodrugs was about 5-fold higher compared to THC, in 
HPβCD. Corneal permeability decreased 3-fold when the donor solution pH was 7.4, probably 
due to ionization of the prodrugs. Dicarboxylic acids are commonly used as promoieties in 
prodrug derivatization approaches to increase the solubility of water insoluble drugs, but their 
acidic pKa values keep them in the ionized state at physiological pH values. When orally 
administered, the gastro intestinal tract (GIT) possesses a large surface area and allows 
prolonged contact time. Also, endogenous ligands could form complexes with ionized drugs 
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when given orally. Thus, even ionized drugs can be absorbed on oral administration over a 
period of time. In contrast, when a drug is instilled topically it has to overcome the limited 
surface area available for absorption and also faces an extremely short contact time. Moreover, 
the mucus lining the corneal epithelial cells is negatively charged and would thus repel the 
negatively charged prodrugs, leading to decreased permeability. A soluble, unionized and highly 
permeable molecule is thus most favorable for ocular delivery.  
Ion-pairing agents have been used to neutralize the charge on ionic drugs and prodrugs 
and to improve ocular permeability (135, 136). l-Arginine carries a positive charge at 
physiological pH and was thus chosen to form an ion-pair complex. Tromethamine, also known 
as tris, is a primary amine and is positively charged at pH 7.4. Tromethamine has been 
successfully used as a counterion for preparing ophthalmic ketorolac formulations (Acular
®
, 
Allergan Inc.).  
THC-HS was found to be highly unstable in the presence of the cationic counterions. At 
the end of the 24 hour equilibration period with l-arginine and tris the prodrug was completely 
converted to THC at all concentrations studied. Further studies of THC-HS with counter-ions 
were discontinued. The maximum aqueous solubility values reported for THC-HG  are  539.56 
µg/mL at pH 8 and 411.3 µg/mL  at pH 9 (128). Improved aqueous solubility of THC-HG with l-
arginine (1.7 mg/mL at pH 8.9, Table 4-2) and tromethamine (1.2 mg/mL, pH 7.8, Table 4-2) in 
IPBS suggests formation of ion-pairs. All further studies with counter-ions were carried out with 
THC-HG.   
At physiological pH values, THC-HG-ARG and THC-HG-TRIS ion-pair complexes in 
IPBS were 7-fold more permeable compared to THC in 2.5% HPβCD in DPBS. The ion-pair 
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complexes demonstrated almost a 1000-fold improvement over the reported permeability of 
THC from light mineral oil based formulations. Three amino acid transporters LAT1, ASCT1 
and B
0,+ 
have been shown to be present and functionally active on the corneal epithelium (98, 99, 
107). l-Arginine utilizes the B
0,+ 
system to permeate though the cornea. B
0,+
 transports amino 
acids which may be neutral or positively charged. Although both L and D amino acids are 
transported, L is more preferred (101). The amino acid transporter B
0,+
 is known to accept a wide 
range of substrates and possibly could tolerate significant structural modifications to their 
substrates. The increased corneal permeability of THC-HG-ARG could be because of the 
involvement of the B
0,+
 system. However, permeability of THC from the THC-HG-ARG 
complex was not inhibited by BCH, indicating that the improvement in physicochemical 
properties was responsible for the observed improvement in permeability. Alternatively, it could 
be speculated that the improvement in permeability could also be due to the positively charged 
counter ions neutralizing the negative charge on the mucous layer covering the corneal 
epithelium.  
Although prodrug derivatization and complex formation improves solubility and corneal 
permeability, the prodrug has to revert back to the parent drug once it reaches the site of action in 
order to elicit pharmacological response. Our results demonstrate that THC-HG undergoes rapid 
bioconversion to THC in the aqueous humor, retina and iris ciliary (Table 4-4). 
The present study has thus lead to the development of a topical drug delivery system 
which improved the solubility and permeability of THC. The THC prodrugs, especially THC-HG 
can thus be formulated as 0.05% topical solutions for future preclinical studies exploring their 
utility in glaucoma.  Considering the promising data obtained with the cyclodextrins in this 
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study, the inclusion complex formed between THC-HG and HPβCD / RMβCD will be 
characterized in the near future, in a manner similar to our previous studies with THC-HS (137).  
4.7. ACKNOWLEDGEMENTS 
This publication was partially supported by grants (1R41EY020042 & 2R42GM067304-
02) from the National Institutes of Health to ElSohly Laboratories, Incorporated. The project was 
also partially supported by grant number 5P20RR021929 form the National Center for Research 
Resources/NIH. The content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institutes of Health. 
 
69 
 
 
CHAPTER 5                                                                                                      
OCULAR DELIVERY AND DISPOSITION OF THE HEMIGLUTARATE 
ESTER PRODRUG OF ∆9-TETRAHYDROCANNABINOL 
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5.1. ABSTRACT 
 
The overall goal of this project is to enhance ocular delivery of ∆9-Tetrahydrocannabinol 
(THC) through the topical route. In this study a relatively water soluble hemiglutarate ester 
prodrug of THC (THC-HG) was evaluated with respect to in vitro and in vivo ocular penetration 
from various ophthalmic formulations. Solubility, stability and in vitro transcorneal permeability 
of THC-HG was studied in the presence of surfactants. The solutions were characterized with 
respect to micelle size, zeta potential and solution viscosity. Effect of BAK and EDTA on in 
vitro transcorneal permeability from the micellar solutions was also studied. In vivo studies were 
carried out with the most promising formulations in New Zealand albino rabbits. A previously 
reported promising THC-HG ion-pair formulation was also studied in vivo.  Total THC 
concentrations produced in the ocular tissues 1h or 3h following topical application was 
determined. Additionally, ocular penetration of THC from mineral oil and emulsion formulations 
was also evaluated. Solubility, stability and in vitro transcorneal permeability of the ester 
prodrug was enhanced significantly in the presence of surfactants. BAK and EDTA led to further 
increase in corneal permeability. THC levels in the ocular tissues (except cornea) were found to 
be below detection limits when THC was formulated in mineral oil, surfactant or emulsion based 
formulations. In contrast, THC-HG micellar and ion pair formulations produced significantly 
higher total THC concentrations in the anterior ocular chamber. In vivo results suggest that the 
lack of activity noted in many of the earlier studies investigating topical THC application could 
be due to inefficient delivery to the targeted ocular tissues. Rational prodrug design and 
formulation development may significantly enhance the utility of this promising compound in 
the management of glaucoma. 
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5.2. INTRODUCTION 
The visual information in the eye is collected in the retina and transmitted to the brain via 
the optic nerve. The amacrine cells and the bipolar cells collect the visual information from the 
rods and the cones in the retina and pass it to the retinal ganglion cells (RGC). The RGC then 
transmits the visual information from the retina to the brain. Glaucoma is an ocular disease 
characterized by progressive and irreversible neurodegeneration of the RGC leading to visual 
field loss(138, 139).  
A number of hypotheses have been presented on what triggers RGC cell apoptosis but the 
exact mechanism is as yet unknown(140). An increase in intraocular pressure (IOP) is a 
significant risk factor in the development and progression of the disease(141). Achieving a 
reduction in intraocular pressure (IOP) has been the mainstay for glaucoma therapy(142). 
However the visual field loss continues even after significant IOP reduction (143, 144). 
Protection of the optic nerve by a mechanism independent of IOP reduction would greatly 
benefit the treatment and management of glaucoma(145). A number of mechanisms such as 
excessive glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, protein 
misfolding and neurotropin withdrawal have been identified as plausible factors for RGC 
apoptosis(140). Memantine, a NMDA receptor blocker, the only drug, to our knowledge, that has 
been studied as a neuroprotectant for glaucoma in phase 3 human clinical trials, failed to meet 
clinical endpoints(146, 147).   
∆9-Tetrahydrocannabinol (THC) is the primary active ingredient of the plant Cannabis 
Sativa. It has shown promise in the treatment of glaucoma due to its IOP lowering and 
neuroprotective effects (23, 24). THC may have an advantage over current class of anti-
glaucoma agents in that in addition to its IOP lowering activity it could act as a neuroprotectant 
through independent mechanisms (124, 148). THC is a partial agonist of both CB1 and CB2 
 72 
 
receptors present in the eye and these might be involved in its IOP lowering and neuroprotective 
activity (44, 47). However, blocking of cannabinoid receptors have failed to completely abolish 
the neuroprotective activity of THC indicating multiple mechanisms might be involved (24, 149, 
150). Evidence now suggests that PPARγ could be an additional target for THC(151). PPARγ 
have been found to be expressed and functionally active in the retina(152). THC could also 
induce vasorelaxation of retinal arteries as well as reduction in ROS activity.   
Literature demonstrates that THC has failed to exhibit consistent IOP lowering and 
neuroprotective activity following topical application(31, 115). The observed inconsistency 
could be due to poor and variable delivery of THC to the target ocular tissues. Formulation of 
THC as an ophthalmic solution is especially challenging due to its low aqueous solubility (1-2 
µg/mL) and high lipophilicity (logP 6.4). Thus, most of the earlier in vivo studies investigating 
the effect of THC through the topical route used mineral oil or emulsion systems as the vehicle. 
In order to improve the physicochemical properties of THC, the relatively water soluble 
hemiglutarate ester prodrug (THC-HG) was synthesized. The goal of this project is to study the 
effect of surfactants on the solubility, stability, in vitro permeability and in vivo bioavailability of 
THC-HG. Effect of benzalkonium chloride (BAK), a preservative, and 
ethylenediaminetetraaceticacid (EDTA), a preservative aid, on in vitro transcorneal permeability 
was also studied. In a previous study, the effect of ion pair formation of THC-HG with 
tromethamine and l-arginine on in vitro transcorneal permeability was reported (148). Both l-
arginine and tromethamine significantly improved transcorneal THC delivery. Thus, the ion-pair 
formulation was also included in this study to compare its in vivo distribution with that of the 
surfactant formulations. Since l-arginine is a biologically active molecule, tromethamine was 
selected as the preferred ion pairing agent.  
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Previous studies exploring the utility of topical THC application in glaucoma, in 
preclinical and clinical studies, have used light mineral oil as the vehicle (31, 50, 116). Some 
studies have also used a submicron emulsion to deliver THC topically (116). Considering that 
the mixed data with respect to the IOP lowering characteristics of topical THC (31, 50, 116) 
could be due to inefficient ocular delivery from these formulations, in the current study we also 
examined the THC levels achieved in the ocular tissues from these formulations. The studies 
thus provide a comparison between the in vivo bioavailability of THC formulated in light mineral 
oil/emulsion/surfactant formulations and THC-HG formulated in micellar or ion-pair solutions.  
 
5.3. METHODS 
5.3.1. Materials 
Super-refined polysorbate 80 was received as a gift sample from Croda Inc (Mill Hall, 
PA). Cremophor RH 40, poloxamer 188 and poloxamer 407 were received as gift samples from 
BASF (Chattanoga, TN) and lipoid E 80 was received as a gift sample from Lipoid 
(Ludwigshafen, Germany). Propofol, sigmacote, hydroxypropyl beta cyclodextrin and tyloxapol 
were purchased from Sigma (St. Louis, MO). All other chemicals were purchased from Fisher 
Scientific (St. Louis, MO). Solvents used for analysis were of HPLC grade.  
5.3.2. Animal Tissues 
Whole eye globes of New Zealand Albino rabbits were purchased from Pel Freez 
Biologicals (Rogers, AK). Eyes were shipped overnight over wet ice in Hanks Balanced Salt 
Solution. Corneas were isolated from whole eye globes and used immediately on receipt. We 
have previously reported that active and passive transport processes in corneas obtained from 
 74 
 
ocular globes stored in Hanks Balanced Salt Solution are equivalent to freshly excised rabbit 
corneas(153).  
5.3.3. Animals 
Male New Zealand White Albino Rabbits were  procured from Harlan Labs 
(Indianapolis, IN). All of the animal experiments conformed to the tenets of the Association for 
Research in Vision and Ophthalmology statement on the Use of Animals in Ophthalmic and 
Vision Research and followed the University of Mississippi Institutional Animal Care and Use 
committee approved protocols. 
5.3.4. Mineral Oil and Emulsion Formulations containing THC 
An accurately weighed amount of THC was dissolved in light mineral oil, NF, to prepare 
the mineral oil based formulation. Emulsion formulations were prepared according to previously 
published protocols (154, 155). However, instead of crude phospholipids, Lipoid E 80 was used. 
The emulsion formulation consisted of super refined soybean oil (14 % w/v), oleic acid (6% 
w/v), glycerin (2.25% w/v), poloxamer 188 (2% w/v), Δ9-tetrahydrocannabinol (1 % w/v), lipoid 
E 80 (1 % w/v), α-tocopherol (0.02% w/v) and deionized water to prepare 20 mL. Briefly, Δ9-
Tetrahydrocannabinol, α-tocopherol and oleic acid were dissolved in super refined soyabean oil. 
Poloxamer and glycerin were dissolved in deionized water. Lipoid E 80 was dispersed in the 
aqueous phase. Both phases were heated to 70 °C. The aqueous phase was added to the oily 
phase and a coarse emulsion was formed by using a high speed homogenizer, Ultra Turrax T25 
(IKA®, Wilmington, NC). The coarse emulsion was then passed through a high pressure 
homogenizer Emulsiflex C5 (Avestin®, Ottawa, Canada). The pH of the final emulsion was 
adjusted to pH 7.4 using 1% w/v sodium hydroxide and it was filtered through a 0.8 µM 
membrane filter.  The drug loading in the final emulsion was determined by HPLC analysis.  
5.3.5. Preparation of THC-HG 
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THC-HG was synthesized as per previously reported procedures(128). 
5.3.6. THC-HG Ion pair formulation 
The formulation was prepared as described in our earlier report(148). Briefly, THC-HG 
(11 mg) was taken from a stock solution (in hexane) in a glass vial and the solvent was 
evaporated under a stream of nitrogen gas. Tromethamine solution (8 mM) prepared in IPBS was 
added to the glass vial. The vial was sonicated for 10 minutes. HPMC (0.5% w/v) was added to 
the formulation and stirred for one hour.  
5.3.7. Solubility of THC-HG in Surfactants  
Excess THC-HG was taken (stock solution 50 mg/mL of THC-HG in hexane) in a glass 
vial. Hexane was evaporated using a stream of nitrogen gas. Isotonic phosphate buffered saline 
(IPBS) containing various types and concentrations of surfactants was then added to the glass 
vials and sonicated for 10 mins. The vials were then placed in a reciprocating water bath (100 
shakes per minute) at  25 °C for a period of 24 hours. The solution was subsequently transferred 
to silicone coated plastic microcentrifuge tubes and centrifuged at 16,000 g for 60 mins (Fisher 
Scientific acuSpin 17R). The supernatant was diluted in mobile phase and taken for analysis.   
Osmolarity of the final solutions was measured using Osmette S (model 4002, Precision 
Systems Inc., Natick, MA) using the freezing point depression method. The instrument was 
calibrated using 100 mOsm and 500 mOsm standards.   
5.3.8. Determination of Micellar Particle Size, Zeta Potential and Viscosity 
A dynamic light scattering instrument, Zetasizer Nano ZS (Malvern Instruments Inc., 
Westbrough, MA) was used for measurements at 25 °C. A high concentration zeta cell was used 
to measure both mean particle size (z averaged) and zeta potential of the micelles. Viscosity 
measurements were carried out at 25 °C (temperature was maintained using a circulating water 
bath) using a Brookfield DV II + Pro cone and plate viscometer. Rheocalc was used as the data 
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acquisition software. Micellar solutions were prepared as described under the solubility studies 
section. Blank vehicles (no drug) were also evaluated. All measurements were carried out in 
triplicate.  
5.3.9. Stability of THC-HG in the Micellar Solutions  
THC-HG loaded micellar solutions were prepared as described under the solubility 
studies section. Stability studies were carried out at 4 °C, 25 °C and 40 °C in glass vials for a 
period of two months. Aliquots taken at predetermined time points were diluted in mobile phase 
and taken for analysis. Apparent degradation rate constants were calculated from the inverse 
slope of a semi logarithmic plot of percentage drug remaining vs time.  
5.2.10. Corneal Permeability Studies 
Corneas were extracted from whole ocular globes by making an incision just below the 
corneal scleral limbus and cutting radially around sclera. It was then mounted between side by 
side permeation cells (Permgear Inc.). Temperature was maintained at 34 °C by circulating water 
through the jacket of the permeation cells. Donor solutions (3 mL), prepared as described under 
solubility studies, was added to the epithelial side (donor cell) and 3.2 mL of 2.5% 
hydroxypropyl beta cyclodextrin solution in IPBS was added to the endothelial side (receiver 
side). The difference in volumes between the donor and the receiver chamber helped maintain 
the natural curvature of the cornea. Aliquots (0.6 mL) were withdrawn every 30 min and 
immediately replaced with donor solution. Samples were taken for analysis.  
5.3.11. In Vivo Bioavailability Studies 
Male New Zealand albino rabbits weighing between 2-2.5 Kg were used for determining 
in vivo bioavailability of THC from the mineral oil/emulsion/micellar formulations and also total 
THC from the prodrug (THC-HG) loaded ion pair and micellar formulations. Rabbits were 
anesthetized using a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg) injected 
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intramuscularly and maintained under anesthesia throughout the experiment.  Topical 
formulations were prepared as described under the solubility section. Fifty microliters of the 
formulations were placed in the cul de sac of the right eye of the anesthetized rabbits. At the end 
of one hour after topical application the rabbits were euthanized by an overdose of pentobarbital 
injected through the marginal ear vein. The eye was washed with ice cold IPBS and immediately 
enucleated and washed again. The ocular tissues were separated, weighed and placed at -80 °C 
until further analysis. All experiments were carried out in triplicate.  
5.3.12. Analytical Procedure for In Vitro Samples 
A Waters HPLC system comprising of 600 E pump controller, 717 plus autosampler and 
2487 UV detector was used. Data handling was carried out using an Agilent 3395 integrator. 
THC and THC-HG stock solutions were prepared in hexane and stored at -15 °C. An 85:15 
mixture of methanol and 0.84% glacial acetic acid was used as a mobile phase on a Phenomenex 
Luna PFP(2) 4.6 x 250 mm column at a flow rate of 1.2 mL/min. Detection was carried out at 
226 nM. Retention time for THC and THC-HG was 10.1 mins and 14.3 mins.     
5.3.13. Bioanalytical Method 
THC-HG was hydrolyzed to THC under alkaline conditions and total THC was 
determined. The hydrolysis process was validated to ensure complete conversion of the prodrug 
to THC. Separate studies have established that THC-HG is rapidly converted to THC in the 
ocular tissue matrix (148). Nevertheless, the additional deconjugation steps were employed to 
ensure conversion of any intact THC-HG into THC.  
Stock solutions of THC, THC-HG and internal standard (propofol) were prepared in 
acetonitrile. THC/THC-HG was spiked in blank ocular tissues and allowed to stand for 15 
minutes before protein precipitation procedure. Standard curves were prepared for THC/THC-
HG in aqueous humor (10 ng – 200 ng), vitreous humor (20 ng-200 ng), cornea (20ng-200ng), 
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iris ciliary body (10ng-200ng), retina choroid (10-200 ng) and sclera (20-200 ng). For THC-HG 
the standard curve was plotted in terms of total calculated THC. Sample preparation for the 
various ocular tissues is described as follows.  
5.3.13.1. Aqueous and vitreous humor sample preparation: To 100 µL of aqueous humor or 
400 µL of vitreous humor 20 µL of drug (10-200 ng) and 20 µL of internal standard (200 ng) 
prepared in acetonitrile was added. To the aqueous humor and vitreous humor samples 50 µL 
and 100 µL of 1N sodium hydroxide was added, respectively, and placed at 25 °C. At the end of 
two hours, 50 and 100 µL of 1N HCl (to neutralize the sodium hydroxide) and 200 µL and 400 
µL of ice cold acetonitrile (to precipitate the proteins) was added to the aqueous humor and 
vitreous humor samples, respectively. All samples were centrifuged at 16,000 g and taken for 
analysis.  
5.3.13.2. Preparation of other ocular tissue samples: To weighed amount of the cornea/iris 
ciliary body/RPE choroid or sclera, 20 µL of drug (20-200 ng) and 20 µL of internal standard 
(200 ng) in acetonitrile was added followed by 600 µL of ice cold acetonitrile and 100 µL of 1 N 
NaOH. The samples were placed at 25 °C and at end of two hours 1N HCl was added. The 
samples were centrifuged at 16000 g for 30 mins and taken for analysis.  
A previously published analytical method using fluorescence detection was modified and 
used(156). For HPLC analysis, a Phenomenex Luna PFP(2) 4.6 x 250 mm column was used. The 
mobile phase consisted of 70% Acetonitrile:30% water containing 5.05% v/v of o-phosphoric 
acid at a flow rate of 1 mL/min. A Waters 2475 detector was set at an excitation wavelength of 
220 nm and THC was detected at emission wavelength of 305 nm. EUFS was set at 150 and gain 
was set at 50. Injection volume was 50 µL. Retention time for propofol and THC were 6.9 mins 
and 11.9 mins respectively. Total runtime was for the method was 20 mins.  
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All standard curves generated had R
2
 values greater than 0.98. Recovery value of THC 
from the ocular tissues was determined at three concentrations (low, medium and high). Average 
recovery values were determined in cornea (99.4 %), aqueous humor (93.2 %), vitreous humor 
(91.2%), iris ciliary body (93.2%), retina (102%) and sclera (91.6%). Limit of detection of THC 
in various ocular tissues were determined in aqueous humor (5ng), vitreous humor (10 ng), 
cornea (10 ng), iris ciliary body (5 ng), retina choroid (5 ng) and sclera (10 ng).   
5.3.14. Data Analysis 
All experiments were carried out at least in triplicate. Flux was obtained from a linear 
regression analysis of the cumulative amount of THC-HG in the receiver chamber versus time. 
Permeability was calculated by normalizing flux values to donor concentrations.  
Unpaired student’s t-test was used to compare between two groups. Statistical analysis 
between multiple groups was carried out by one way analysis of variance. Levenes test was used 
to find out variation between the groups. Tukey’s Honestly Significant test was used to 
differentiate between the groups. p < 0.05 was considered to be statistically significant.  
5.4. RESULTS 
5.4.1. Solubility and Osmolarity in Surfactant Solutions  
Use of surfactants led to a significant improvement in the aqueous solubility of THC-HG 
(Table 5-1). At 0.1% w/v, Polysorbate 80 led to the greatest increase in solubility (36-fold, 678.2 
± 23.4 µg/mL) followed by Poloxamer 407 (29-fold, 507.4 ± 6.6 µg/mL), Tyloxapol (24-fold, 
467.6 ± 27.9 µg/mL) and Cremophor RH 40 (22-fold, 424.9 ± 60.5 µg/mL) respectively. 
Poloxamer 188 led to only a 6-fold improvement in solubility and was thus not studied any 
further. Solubility of THC-HG was further studied at higher concentration of Cremophor RH 40 
and Poloxamer 407 (maximum concentrations approved for ophthalmic formulations). Solubility 
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of THC-HG in 0.25% w/v and 0.5% w/v of Cremophor RH 40 was found to be 890.7 ± 166.2 
µg/mL and 2136.2 ± 112.7 µg/mL, respectively. Solubility of THC-HG at 0.16% Poloxamer 407 
was found to be 621.9 ± 77.1 µg/mL.  
Inclusion of surfactants and THC or THC-HG in the formulations did not change the 
osmolarity significantly at the concentrations studied. 
 
Table 5-1: Solubility and Osmolarity of THC-HG in Cremophor RH 40, Poloxamer 188, 
Poloxamer 407, Polysorbate 80 and Tyloxapol in IPBS at 25 °C. Results are depicted as mean ± 
SD (n=3). 
 
Excipient 
Concentration                 
(% w/v) 
THC-HG 
Solubility 
(µg/mL) 
Osmolarity 
(mOsm) 
Plain IPBS - 18.8 ± 3.1 281.6 ± 1.7 
Cremophor RH 40 
0.1 424.9 ± 60.5 282.6 ± 0.5 
0.25 890.7 ± 166.2 284.3 ± 0.5 
0.5 2136.2 ± 112.7 292.3 ± 1.2 
Poloxamer 188 0.1 106.8 ± 23.4 282 ± 2.2 
Poloxamer 407 
0.1 507.4 ± 6.6 282.9 ± 1.2 
0.16 621.9 ± 77.1 283.6 ± 0.5 
Polysorbate 80 0.1 678.2 ± 23.4 282.6 ± 0.5 
Tyloxapol 0.1 467.6 ± 27.9 283 ± 0.8 
  
 
Table 5-2: Hydrodynamic Radius, D90 and Zeta Potential of blank and THC-HG loaded (DL) micelles prepared in IPBS at 
25 °C.  Results are depicted as mean ± SD (n=3). 
 
Surfactant Concentration                   
(% w/v) 
Hydrodynamic 
Radius 
(nm) 
D90 
(nm) 
PDI 
Zeta 
Potential 
(mV) 
Viscosity 
(Cp) 
Cremophor 
RH 40 
0.1 
Blank 9.4 41.8 ± 3.7 0.259 1.0 1.2 ± 0.01 
DL 16.4 68.4 ± 6.9 0.220 -6.4 1.26 ± 0.01 
0.25 
Blank 7.9 27.5 ± 0.6 0.135 0.4 1.23 ± 0.03 
DL 11.3 41.2 ± 1.6 0.164 -6.4 1.25 ± 0.01 
0.5 
Blank 7.6 27.2 ± 0.8 0.081 -1.2 1.25 ± 0.02 
DL 14 69.3 ± 3.1 0.322 -6.6 1.28 ± 0.02 
Poloxamer 
407 
0.16 
Blank 8.1 30.7 ± 2.9 0.162 -2.3 1.22 ± 0.02 
DL 15.9 61.7 ± 7.4 0.264 -5.5 1.24 ± 0.01 
Polysorbate 
80 
0.1 
Blank 11.1 36.6 ± 6 0.152 -1.4 1.22 ± 0.01 
DL - - - -11 1.26 ± 0.01 
Tyloxapol 0.1 
Blank 6.8 25.1 ± 1.5 0.154 0.1 1.20 ± 0.01 
DL 14.3 65.1 ± 8.3 0.237 -15.8 1.24 ± 0.01 
8
1
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5.4.2. Particle Size and Viscosity Measurements 
The hydrodynamic radius, D90 and zeta potential of the blank and THC-HG loaded 
surfactant formulations are presented in Table 5-2.  
5.4.3. Stability in Presence of Surfactants  
The hydrolysis of THC-HG followed first order degradation. Apparent first order 
hydrolysis rate constants and half-life of THC-HG in the presence of surfactants is presented in 
Table 5-3. Stability of THC-HG was enhanced significantly in the presence of surfactants and 
was found to be temperature dependent. Energy of activation was calculated from the Arrhenius 
Plot constructed with the data. Formulations containing Poloxamer 407 had the lowest energy of 
activation (984 cal/mol). Energy of activation of THC-HG in the presence of Polysorbate 80 
(2161 cal/mole), Tyloxapol (2354 cal/mol) and Cremophor RH 40 (2330 cal/mol) was not 
significantly different.  
5.4.4. Permeability of THC-HG in the presence of surfactants 
Permeability of THC-HG in the presence of 0.1% w/v Cremophor RH 40 was found to be 
14 x 10
-6
 cm/s. Increasing the concentration of Cremophor RH 40 to 0.25 % w/v (10.5 x 10
-6
 
cm/s) and 0.5 % w/v (10.9 x 10
-6
 cm/s) did not affect the permeability significantly. Permeability 
of THC-HG in the presence of 0.16 % w/v Poloxamer 407 was found to be slightly higher (21.4 
x 10
-6
 cm/s compared to 0.1 % w/v (15 x 10
-6
 cm/sec). In the presence of 0.1 % Polysorbate 80 
and Tyloxapol permeability was found to be 7.3 x 10
-6
 cm/s and 12.3 x 10
-6
 cm/s, respectively. 
The above data have been illustrated in Fig. 5-1.  
Since Cremophor RH 40 and Poloxamer 407 containing formulations demonstrated the highest 
permeability, the effect of inclusion of BAK and EDTA on permeability was also studied. 
However, Poloxamer 407 interacted with BAK and led to the formation of a precipitate. Hence 
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the effect of BAK on the permeability of poloxamer 407 based formulations could not be 
studied. Permeability of THC-HG in 0.01% w/v BAK and 0.1% w/v of Cremophor RH-40 was 
significantly increased to 19.9 x 10
-6
 cm/s (Fig. 5-2). Use of 0.02% BAK in 0.1 % w/v 
Cremophor RH 40 led to a two-fold enhancement in permeability of THC-HG. Addition of 0.1% 
w/v disodium EDTA to the 0.1%  Cremophor RH 40 formulation also led to a significant 
increase in the permeability of THC-HG (18.6 x 10
-6
 cm/s). A combination of 0.01% BAK with 
0.1% disodium EDTA in 0.1% Cremophor RH 40 yielded a permeability value of 24.2 x 10
-6
 
cm/s.  
 
Table 5-3: Apparent first order rate constants (k* x 10
4
,
 
h
-1
)
 
and half lives (t1/2, days) of THC-
HG in various surfactant solutions in IPBS at 4 °C, 25 °C and 40 °C.  Results are depicted as 
mean ± SD (n=3).  
 
 
Formulation 
Concentration 
(% w/v) 
 4 °C 25 °C 40 °C 
IPBS 0.001 
k 161 ± 34.5 1755.7 ± 84.3 2556.7 ± 97.4 
t1/2 45.5 ± 11.3 3.9 ± 0.2 2.7 ± 0.1 
Cremophor RH 
40 
0.1 
k 1.9 ± 0.4 5.3 ± 0.1 13.6 ± 0.4 
t1/2 155.3 ± 34.4 54.2 ± 0.5 21.1 ± 0.6 
Poloxamer 407 0.1 
k 4.4 ± 1.8 6.8 ± 0.4 17.5 ± 0.6 
t1/2 77.1 ± 30.1 42.2 ± 2.3 16.4 ± 0.6 
Polysorbate 80 0.1 
k 1.7 ± 0.2 4.3 ± 0.1 10.7 ± 0.5 
t1/2 167.7 ± 15.6 67.7 ± 2 27.1 ± 1.2 
Tyloxapol 0.1 
k 1.8 ± 0.5 4.5 ± 0.1 13 ± 3.5 
t1/2 174.9 ± 52.4 64.7 ± 1.8 23.7 ± 5.4 
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Figure 5-1: Permeability of THC-HG from various surfactant solutions across isolated rabbit 
cornea at 34 °C. Receiver solution consisted of IPBS containing 2.5% HPβCD (pH 7.4). Results 
are depicted as mean ± SD (n=4). *p<0.05.   
 
 
Figure 5-2: Permeability of THC-HG from donor solutions containing Cremophor RH 40, BAK 
and/or EDTA across isolated rabbit cornea at 34 °C. Receiver solution used was IPBS containing 
2.5% HPβCD (pH 7.4). Results are depicted as mean ± SD (n=4). *p<0.05.   
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5.4.5. In Vivo Bioavailability 
The THC or THC equivalent (for the THC-HG formulation) content in the formulations 
are provided in Table 5-4 and Table 5-5. THC formulated in mineral oil (0.1%) or as emulsions 
(0.4%) did not produce any detectable THC levels in the aqueous humor or the iris ciliary body. 
On the other hand, THC-HG formulation (0.18% THC equivalent) consisting of 0.5% 
Cremophor RH 40 + 0.02 % BAK + 0.1 % EDTA + 0.5 % HPMC delivered 32.1 ± 12.6 ng/100 
µL to the aqueous humor and 35.6 ± 12.5 ng/50 mg to the iris ciliary body. THC-HG ion pair 
formulation (0.16% THC equivalent) was able to deliver 52.2 ± 18.7 ng/100 µL to the aqueous 
humor and 93.1 ± 41.4 ng/50 mg to the iris ciliary body. THC concentrations achieved in the 
cornea from the THC-HG formulation in cremophor (2451.6 ± 645.6 ng/50 mg) and ion pair 
formulations (2245.7 ± 240.2 ng/50 mg) were several fold greater than that obtained from the 
THC loaded mineral oil (68.8 ± 14.5 ng/50 mg) and emulsion (300.6 ± 79.6 ng/50 mg) 
formulations. THC-HG containing micellar solution (354.7 ± 86.4 ng/250 mg) as well as ion pair 
formulation (2258.1 ± 1331.8 ng/250 mg) also delivered significantly higher concentration to the 
sclera compared to light mineral oil (104.1 ± 36.1 ng/250 mg) and emulsion (171.1 ± 66.6 
ng/250 mg) THC formulations.  
Intraocular tissue concentrations 3h post instillation of the ion pair formulations were also 
determined since significantly higher concentrations of THC were detected in the iris ciliary 
body from this formulation when compared to the surfactant formulation. THC concentrations in 
the cornea (1382.7 ± 109.8 ng/50 mg), aqueous humor (27.3 ± 11.3 ng/100 µL), iris ciliary (67.1 
± 55.6 ng/50 mg) and sclera (166.1 ± 49.3) were still detected at the end of three hours.  
When THC, rather than THC-HG, was incorporated into the Cremophor based micellar 
solution (0.125% w/v THC, 0.5% Cremophor RH 40, 0.02% BAK, 0.1% EDTA, 0.5% HPMC) 
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THC was detected in the cornea (553.9 ± 87.4 ng/ 50 mg tissue) and sclera (354.7 ± 86.4 ng/250 
mg tissue but  not in the aqueous humor or  iris ciliary body. the retina choroid. 
However, none of the formulations studied produced THC concentrations  in the vitreous 
humor (LOD 5ng/400 µL) or the retina choroid (LOD 10 ng/ 50 mg of tissue). The above results 
have been presented in Tables 5-4 and 5-5. 
 
Table 5-4: Total THC concentrations observed in rabbit ocular tissues 1 h post topical 
administration of 50 µL of THC in Light Mineral Oil (0.1% w/v), Emulsion (0.4% w/v) or 
micellar solutions (0.125 % w/v THC, 05% Cremophor RH 40 + 0.1% EDTA + 0.02% BAK + 
0.5% HPMC). Results are depicted as mean ± SD (n=3).  
 
 
Tissue 
THC 
Light Mineral 
Oil 
Emulsion 
0.5% Cremophor RH 
40 + 0.1% EDTA + 
0.02% BAK + 0.5% 
HPMC 
Drug Concentration in 
terms of THC 
(% w/v) 
0.1 0.37 0.125 
Cornea 
(ng/50 mg Tissue) 
68.8 ± 14.5 300.6 ± 79.6 553.9 ± 87.4 
Aqueous Humor 
(ng/100 µL) 
ND* ND* ND* 
Iris-Cilliary Body 
(ng/50 mg Tissue) 
ND* ND* ND* 
Vitreous Humor 
(ng/mL) 
ND* ND* ND* 
Retina-Choroid 
(ng/50 mg Tissue) 
ND* ND* ND* 
Sclera 
(ng/250 mg Tissue) 
104.1 ± 36.1 171.1 ± 66.6 439.3 ± 280.2 
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Table 5-5: Total THC concentrations observed in rabbit ocular tissues 1 h post topical 
administration of 50 µL of THC-HG in or THC-HG (0.2 % w/v THC equivalent) formulated in, 
05% Cremophor RH 40 + 0.1% EDTA + 0.02% BAK + 0.5% HPMC or ion pair formulation (8 
mM tromethamine + 0.5% HPMC). Results are depicted as mean ± SD (n=3).  
 
 
5.5. DISCUSSION 
Helper and Frank in 1971 observed that smoking marijuana leads to a drop in IOP and 
subsequently THC was identified as one of the constituents responsible(157). Several preclinical 
Tissue 
THC-HG 
0.5% Cremophor 
RH 40 + 0.1% 
EDTA+0.02% 
BAK + 0.5% 
HPMC 
Ion Pair Formulation 
1 Hour 1 Hour 3 Hours 
Drug Concentration 
in terms of THC 
(% w/v) 
0.18 0.16 0.16 
Cornea 
(ng/50 mg Tissue) 
2451.6 ± 645.6 2245.7 ± 240.2 1382.7 ± 109.8 
Aqueous Humor 
(ng/100 µL) 
32.1 ± 12.6 52.2 ± 18.7 27.3 ± 11.3 
Iris-Cilliary Body 
(ng/50 mg Tissue) 
35.6 ± 12.5 93.1 ± 41.4 67.1 ± 55.6 
Vitreous Humor 
(ng/mL) 
ND* ND* ND* 
Retina-Choroid 
(ng/50 mg Tissue) 
ND* ND* ND* 
Sclera 
(ng/250 mg Tissue) 
354.7 ± 86.4 2258.1 ± 1331.1 166.1 ± 49.4 
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and clinical studies were initiated to determine whether THC could lower IOP when applied 
topically. However the results were ambiguous. One of the reasons behind the observed 
variability could be lack of an effective ophthalmic THC formulation in these earlier studies. The 
ocular tissues presents significant physiological barriers to the permeation of external moieties 
e.g. tear flow, corneal ultrastructure and aqueous humor outflow (158). Delivery to the posterior 
segment of the eye is even more challenging (159). On top of these factors, THC is a highly 
lipophilic agent and will not efficiently partition into the aqueous precorneal environment from 
lipophilic formulations to be available for ocular absorption. In this study, the in vitro 
transcorneal permeability and in vivo bioavailability of THC has been improved using a 
combination of hydrophilic prodrug derivatization and formulation approaches. Ocular 
bioavailability using the prodrug, through the topical route, has also been compared to that of 
THC from mineral oil and emulsion based formulations, similar to that used in the earlier in vivo 
studies.   
In order to increase the aqueous solubility, stability and permeability of THC-HG, 
surfactants commonly used in ophthalmic formulations were used. The maximum surfactant 
concentrations to be used in these studies were determined from the FDA database of inactive 
excipients.  
Use of surfactants led to a significant improvement in the aqueous solubility of THC-HG. 
Moreover, the ester hydrolysis rate constant of THC-HG was significantly reduced in the 
presence of the surfactants leading to a marked improvement in the stability of THC-HG in 
aqueous solutions.  
Amongst the surfactants studied, THC-HG demonstrated highest in vitro transcorneal 
permeability in the presence of poloxamer 407 and this formulation was thus selected for further 
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evaluation. Although the extent of permeation enhancement achieved with Cremophor RH 40 
was less marked than poloxamer 407, Cremophor RH 40  has been used at concentrations up to 
0.5% in ophthalmic eyedrops, in contrast to only 0.16% for poloxamer, and can thus provide 
advantages with respect to higher donor concentrations and flux. Thus, both poloxamer 407 and 
Cremophor RH 40 were investigated further.  
BAK, a cationic surfactant, is commonly used as a preservative in ophthalmic 
formulations. Preservative action is primarily dependent on free BAK concentration present in 
the formulation. BAK is known to interact with some surfactants, leading to loss of antimicrobial 
activity (160). THC-HG being a weak acid is negatively charged at physiological pH and may 
also interact with positively charged BAK. Moreover, BAK is also known to act as a 
permeability enhancing agent (113). Thus, the effect of inclusion of BAK and EDTA in the 
promising THC-HG surfactant formulations was also investigated. 
Surfactant micelles present in dilute solutions usually form spherical/ellipsoid micelles. 
At higher surfactant concentrations micelles undergo transformation from spherical/ellipsoid to 
cylindrical shapes which is usually associated with a significant increase in viscosity(161). Since 
the viscosity of the drug loaded micellar formulations did not change significantly it probably 
indicates that the drug loaded micelles were mostly spherical/ellipsoid in shape. Literature 
reports also suggest that surfactants listed in Table 5-2 form spherical/ellipsoid shaped micelles 
in dilute solutions (162-166).  
Poloxamer 407 demonstrated the highest in vitro permeability but addition of 0.02 % 
BAK to the formulation led to the formation of a precipitate. Formation of a precipitate was 
however not observed with the blank (no drug added) vehicle. Thus, the observed precipitation 
could be due to an interaction of BAK with THC-HG. Poloxamer 407 was thus not studied any 
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further with respect to THC-HG formulation.  In contrast to the results with poloxamer 407, a 
clear solution could be prepared with BAK and Cremophor RH 40 formulation. This could be 
due to better shielding of the HG promoiety of THC-HG in the Cremophor RH 40 micelles or 
packing characteristics of the Cremophor RH 40 micelles.  
Based on the in vitro permeability and solubility data the Cremophor RH 40 based 
formulation was selected for in vivo evaluation in rabbits. Since, permeability of THC-HG in 
Cremophor RH 40 was found to be independent of the surfactant concentration (within the range 
studied), 0.5% Cremophor RH 40 concentration, which allowed 2.1 mg/mL of THC-HG loading, 
was selected for the in vivo studies. BAK (0.02%) and EDTA (0.1%) were also included in the 
formulation in view of their permeability enhancing effect and their common role as 
preservatives in ophthalmic formulations(160). To increase the corneal residence time 0.5% 
hydroxyl propyl methyl cellulose (HPMC) was added to the formulation as a viscosity enhancer.   
In an earlier study Green et al reported intraocular tissue concentration of radiolabelled 
THC (0.1% w/v) formulated in light mineral oil. Approximate THC concentrations have been 
reported in the cornea (100 ng/50 mg of tissue), iris-ciliary body (15 ng/50 mg) and the aqueous 
humor (4 ng/100 µL) at the end of one hour(50).  
In the current study, topical administration of 0.1% THC in mineral oil produced similar 
THC concentrations (68.8 ng ± 14.5 ng/50mg) in the cornea. However, THC levels in the 
aqueous humor and the iris ciliary body were found to be below the detection limits of the 
analytical method used in this study. The 0.4% w/v THC emulsion formulation was also not able 
to deliver THC to the intraocular tissues. These results suggest that, in the earlier studies, THC 
was probably not achieving significant concentrations in the targeted ocular tissues with the 
mineral oil and emulsion formulations.  
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Use of the relatively hydrophilic HG ester prodrug of THC and incorporation into a 
micellar solution markedly improved the delivery of THC to the aqueous humor) and the iris 
ciliary body. This indicates that the prodrug was able to partition from the vehicle into the ocular 
tissues more efficiently. To delineate the effect of the prodrug from the surfactant system, THC 
(0.125% w/v) was applied topically in the same vehicle. In this case THC levels were not 
detected in the aqueous humor, iris ciliary body, vitreous humor and the retina choroid. This 
strongly suggests that, chemical modification of THC into THC-HG led to a significant 
improvement in the physicochemical properties allowing better partitioning into the aqueous tear 
fluid and from there into the cornea and other intraocular tissues. However, THC levels in the 
back-of-the eye tissues were still not observed.  
Ion pair formulation of THC-HG with tromethamine delivered significantly higher 
concentrations to the iris ciliary body compared to micellar formulation Although rapidly cleared 
from the back-of-the eye ocular tissues, significant THC concentrations were still detectable in 
the aqueous humor and iris ciliary body at the end of three hours. However, even the ion pair 
formulation was unable to deliver THC to the back of the eye tissues. Thus, to utilize the 
neuroprotective potential of THC, further improvement in the topical delivery system is needed.  
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CHAPTER 6                                                                                                     
EVALUATION OF AMINO ACID AND AMINO ACID-DICARBOXYLIC 
ACID CONJUGATED Δ9- TETRAHYDROCANNABINOL PRODRUGS 
FOR TOPICAL DELIVERY 
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6.1. ABSTRACT 
 
The aim of the present study was to determine the preformulation characteristics of Δ9-
Tetrahydrocannabinol (THC) prodrugs, and to study their ocular disposition following topical 
instillation. Synthesis and preformulation characterization was carried out for amino acid based 
Δ9-Tetrahydrocannabinol (THC) prodrugs. An amino acid-dicarboxylic acid conjugate prodrug 
of THC, THC-Valine-Hemisuccinate (THC-Val-HS), was also synthesized. In vitro transcorneal 
permeability of the prodrugs in the presence of solubilizing agents was studied across isolated 
rabbit cornea using a side by side diffusion apparatus. Promising formulations were selected for 
in vivo ocular bioavailability studies in the anesthetized rabbit model. Amino acid based THC 
prodrugs, THC-Val and THC-Val-Val, revealed poor solubility characteristics at physiological 
pH and were thus not studied any further. THC-Val-HS, however, demonstrated much improved 
solubility and also in vitro transcorneal permeability at pH 7.4, compared to THC.   Formulation 
of THC-Val-HS as an aqueous eye drop was most effective in delivering THC to the anterior 
chamber of the eye. However, THC was below quantifiable levels in the vitreous humor and the 
retina-choroid tissue from this formulation. THC-Val-HS in a polymeric delivery system 
produced significant THC concentrations in both anterior and posterior ocular chambers. A 
combination of prodrug derivatization and formulation development approaches significantly 
improved delivery of THC into the anterior and posterior segments of the eye.  
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6.2. INTRODUCTION 
Δ9-Tetrahydrocannabinol (THC), an active ingredient of the plant cannabis sativa, could 
potentially be a dual acting antiglaucoma agent(23, 24, 124). In addition to intraocular pressure 
(IOP) lowering effect, it could also demonstrate an independent neuroprotective activity(148). 
Since 1970`s a lot of studies have been carried out to elucidate the pharmacological activity but 
the outcome has been inconclusive due to mixed results (31, 167, 168). We have previously 
studied dicarboxylic acid prodrugs of THC to improve ocular bioavailability(148). These 
prodrugs were ionized at physiological pH values and various formulation approaches were 
adopted to improve transcorneal permeation. In this study we synthesized and evaluated a series 
of amino acid prodrugs including valine (THC-Val) and valine-valine (THC-Val-Val) as well as 
an amino acid dicarboxylic acid conjugate, valine hemisccinate (THC-Val-HS), ester prodrugs of 
THC for ocular bioavailability.  
Topical eye drops are the most preferred means of drug delivery to the eye. But delivery 
of THC as an eye drop is especially challenging due to its low aqueous solubility (1-2 µg/mL) 
and high logP (6.42)(127). To improve solubility, THC has been formulated in lipophilic 
vehicles, complexed with cyclodextrins and incorporated in submicron emulsions(51, 127, 169). 
These approaches have helped improve the solubility of THC but due to its high lipophilicity 
most of the drug gets entrapped in the corneal epithelium and does not reach the targeted ocular 
tissues (iris ciliary body and retina). The dose of the topically applied THC has to be increased to 
improve flux, which leads to increased systemic exposure. THC being a psychoactive drug, 
increased plasma drug load may lead to undesirable side effects.  
Tear formation in the precorneal area leads to rapid dilution and drainage of topically 
applied drug(170). Since volume of the eye drop administered is relatively constant, higher drug 
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solubility helps increase drug concentration in the precorneal area and thus increases transcorneal 
flux. Another significant barrier to drug permeability is the presence of intercellular tight 
junctions (zona ocludens) on the corneal epithelium which restricts transcellular 
permeability(171). High lipophilicity improves transepithelial permeability through the 
transcellular route. However, high lipophilicity and low aqueous solubility prevents effective 
partitioning in the stroma and thus lowers intraocular drug bioavailability. Thus, desired 
physicochemical properties for topically applied drugs are high aqueous solubility and logP 
values between 2-3(172). Since formulation approaches failed to deliver sufficient THC 
concentrations to the intraocular tissues, THC prodrugs were synthesized. Prodrug approach in 
drug delivery is commonly utilized to improve the physicochemical properties of the parent 
compound (173). Prodrugs, in addition to improving physicochemical properties, can also be 
used to target amino acid and peptide transporters that can help improve transcorneal 
permeability by piggybacking drug through nutrient barriers(101).  
Valine ester prodrugs of acyclovir and gancyclovir (valcyclovir and valgancyclovir) have 
demonstrated significant improvement in aqueous solubility and transcorneal permeability(97). 
Thus, the amino acid based hydrophilic prodrug derivatization approach was adopted in this 
study to evaluate its effect on the disposition of topically administered THC into the deeper 
ocular tissues. 
6.3. METHODS 
6.3.1. Materials 
6.3.1.1. Chemicals 
Hydroxypropyl beta cyclodextrin (HPβCD), randomly methylated beta cyclodextrin 
(RMβCD), hydroxypropyl methyl cellulose (HPMC, 3000 cps) and tyloxapol were purchased 
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from Sigma (St. Louis, MO). Super refined polysorbate 80 was received as a gift sample from 
Croda Inc. (Mill Hall, PA). Poloxamer 188, Poloxamer 407 and Cremophor RH 40 were received 
as a gift sample from BASF (Florham Park, NJ). Polyethyleneoxide (PolyOx N10) was received 
as a gift sample from Dow Chemical Company (Midland, MI). All other chemicals and solvents 
were purchased from Fisher Scientific (St. Louis, MO).   
 
 
Figure 6-1: Chemical structures of A) Δ9-Tetrahydrocannabinol (THC) B) Δ9-
Tetrahydrocannabinol Valine (THC-Val) C) Δ9-Tetrahydrocannabinol-Valine-Valine (THC-Val-
Val) and D) Δ9-Tetrahydrocannabinol Valine Hemisuccinate (THC-Val-HS). 
 
6.3.1.2. Animal Tissues 
Earlier studies in the laboratory have reported the effect of storage on active and passive 
diffusion processes across the cornea(153). Whole eye globes of New Zealand Albino rabbits, 
purchased from Pel Freez Biologicals (Rogers, AK), were shipped overnight over wet ice in 
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Hanks Balanced Salt Solution. Corneas isolated from whole eye globes were used for in vitro 
permeability studies immediately on receipt.  
6.3.1.3. Animals 
Male New Zealand Albino Rabbits (2-2.5 kg) were procured from Harlan Labs 
(Indianapolis, IN). All of the animal experiments conformed to the tenets of the Association for 
Research in Vision and Ophthalmology statement on the Use of Animals in Ophthalmic and 
Vision Research and followed the University of Mississippi Institutional Animal Care and Use 
committee approved protocols. 
6.3.2. Synthesis of Δ9-Tetrahydrocannabinol Prodrugs 
The prodrugs were synthesized by Dr. Waseem Gul of ElSohly Laboratories. Structures 
of THC, THC-Val, THC-Val-Val and THC-Val-HS are depicted in Fig. 6-1.  
6.3.3. Solubility Studies 
Standard shake flask method was used for the determination of prodrug solubility in 
aqueous solutions. For pH dependent solubility, buffers at pH 3, pH 5, pH 7 and pH 9 were 
prepared according to USP XXX. Surfactant solutions at various concentrations were prepared in 
Isotonic Phosphate Buffered Saline (IPBS). Excess drug from an acetonitrile stock solution was 
added to a glass vial and the organic solvent was evaporated in a vacuum chamber. Buffers or 
surfactant solutions were added to the glass vials and the solutions were equilibrated at 25 °C in 
a shaking water bath for 24 hours. The solutions were transferred to silicon coated tubes and 
centrifuged at 16000g in a Fisher Scientific acuSpin Micro 17R for 30 mins. The supernatant was 
diluted in mobile phase and analyzed by HPLC. All experiments were carried out in triplicate. 
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6.3.4. Preparation of Polymeric Film 
Hot melt cast method was utilized to prepare the polymeric film. Polyethyleneoxide (MW 
100000 Daltons) was used as the matrix forming material. THC-Val-HS was dissolved in 
acetonitrile and dispersed in polyethylene oxide with adequate mixing. The mixture was placed 
in a vacuum oven to evaporate the organic solvent. A 13 mm die was placed over a brass plate 
and the brass plate was heated to 70 °C using a hot plate. The drug-polymer mixture was placed 
in the center of the die, compressed and was heated further for 2-3 mins. Following cooling 4 
mm x 2 mm film segments were cut from the extrudate. To determine the content, the film was 
placed in 10 mL of acetonitrile and sonicated for 15 mins. The film dissolved completely in 
acetonitrile. The solution was then analyzed by HPLC.  
6.3.5 Stability of THC-Val-HS in the presence of surfactants and cyclodextrins 
THC-Val-HS loaded micellar solutions and cyclodextrin complexes were prepared as 
described under the solubility studies section. Stability studies were carried out at 4 °C, 25 °C 
and 40 °C in glass vials for a period of two weeks. Aliquots taken at predetermined time points 
were diluted in mobile phase and taken for analysis. Apparent degradation rate constants were 
calculated from the inverse slope of a semi logarithmic plot of percentage drug remaining vs 
time.  
6.3.6. Corneal Permeability Studies 
Method to isolate corneas from whole ocular globes has been described earlier(153). 
Isolated corneas were placed between jacketed side by side diffusion cells (PermeGear Inc, 
Hellertown, PA) maintained at 34 °C using a circulating water bath. Donor solution (3mL) was 
added to the side of cornea facing the epithelium and 3.2 mL of 2.5% HPβCD in IPBS was used 
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as the receiver chamber. Aliquots (0.6 mL) were taken every 30 mins for 3 hours and replaced 
with an equal volume of fresh buffer. Samples were analyzed by HPLC.  
6.3.7. In Vivo Bioavailability Studies 
In vivo bioavailability of formulations was determined in Male New Zealand albino 
rabbits weighing between 2-2.5 Kg. Rabbits were administered ketamine (35 mg/kg) and 
xylazine (3.5 mg/kg) intramuscularly and maintained under anesthesia throughout the 
experiment. The rabbits were placed on one side and 50 µL of the formulations was placed in the 
cul de sac. The polymeric film was placed 2 mm below the corneoscleral junction. No ocular 
irritation was observed in all of the formulations applied. Rabbits were sacrificed at 1 or 3 hours 
after dosing with an overdose of pentobarbital. The eyes were washed thoroughly with ice cold 
IPBS and immediately enucleated. The various ocular tissues were separated and placed at -80 
°C until further analysis. All experiments were carried out in triplicate. A previously published 
method to determine THC concentration in ocular tissues was adopted after necessary validation.  
6.3.8. Analytical Method for In Vitro Samples 
A HPLC system consisting of a Waters 717 plus autosampler, 600E pump controller, 
2487 UV detector and an Agilent 3395 integrator was used for analysis. An analytical method 
was developed for the determination of THC-Val and THC-Val-Val. Stock solutions of the 
prodrugs were prepared in acetonitrile and used immediately. A Luna PFP(2) column (4.6 mm x 
250 mm) was used for analysis. Mobile phase developed was 10 mM phosphate buffer at pH 
7.35 and acetonitrile in the ratio of 1:3 at a flow rate of 1.2 mL/min. Standard curves were 
generated from 0.2 µg- 10 µg/mL with an R
2
 value greater than 0.9999. Retention time was 8.5 
min for THC, 11.5 min for THC-Val and 13.5 min for THC-Val-Val.   
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Determination of THC in ocular tissues was carried out as described previously. A 
protein precipitation method was used for isolation of the prodrug and the drug from the ocular 
tissue homogenates.  All of THC-Val-HS and other intermediates were converted to THC by 
carrying out alkaline hydrolysis at room temperature for 1 hour. The homogenate was neutralized 
by the addition of hydrochloric acid and centrifuged. The supernatant was separated and 
analyzed by HPLC-fluorescence method previously described.  
6.3.9. Data Analysis 
Flux and in vitro permeability was determined as previously reported(153). Difference in 
variance between the groups was checked with Levenes test before carrying out ANOVA. 
Statistical significant difference among multiple groups was checked using one way ANOVA. 
Tukey’s Honestly Significant test was carried out to differentiate between the groups. A p values 
less than 0.05 was considered to be statistically significant.  
6.4. RESULTS 
6.4.1. Predicted Physicochemical Properties 
Unionized drug in solution is preferred since permeation of unionized drug is greater 
compared to ionized drug. The predicted pKa values (ACD ILab 2.0) for mono- and di- amino 
acid THC prodrugs were found to be close to the physiological pH values. Thus, a greater 
fraction of the drug would remain in the unionized state at physiological pH values.  On the other 
hand, THC-Val-HS is a weak acid with a predicted pKa value of 4.7 ± 0.1.  Although logP 
values did not change significantly for the prodrugs synthesized, logD (pH 7.4) values were 
lower. The predicted values are presented in Table 6-1. .   
6.4.2. Solubility studies 
 101 
 
Aqueous solubility of THC-Val and THC-Val-Val was below the detection limit of the 
analytical method used (<1 µg/mL). Some of the other amino acid THC prodrugs, THC-
glutamine, THC-sarcosine and THC-serine, demonstrated significantly higher aqueous solubility 
but they had extremely short half-lives in aqueous solutions. On the other hand, aqueous 
solubility and stability of THC-Val-HS was found to be significantly higher in the physiological 
pH range, compared to THC and all the other prodrugs tested (Table 6-2). 
In view of the higher stability of THC-Val, THC-Val-Val and THC-Val-HS solubility 
was tested further as a function of pH. THC-Val and THC-Val-Val solubility in the buffers was 
found to be below detection limits (<1 µg/mL) within the pH range studied. pH dependent 
solubility of THC-Val-HS was also studied at pH 3 (Not detected, < 1µg/mL), pH 5 (1.3 ± 0.1 
µg/mL), pH 7 (76.8 ± 12.9 µg/mL) and pH 9 (141.8 ± 32.9 µg/mL).  
 
Table 6-1: Predicted Physicochemical Properties of Amino Acid Prodrugs using ACD-I Lab 2.0. 
Pro-Drug 
ACD I-Lab Predicted Values 
Molecular 
Weight 
pKa logP 
logD   
(pH 
7.4) 
Solubility 
(µg/mL) 
Polar 
Surface 
Area 
THC 314.2 9.8 ± 0.6 
6.8 ± 
0.4 
7.1 1.0 29.5 
THC-Val 413.6 7.5 ± 0.3 
6.7 ± 
0.4 
6.3 0.83 61.6 
THC-Val-Val 512.7 
8.2 ± 0.3 7.4 ± 
0.6 
5.9 0.79 90.7 
13.4 ± 0.5 
THC-Valine-HS 513.6 
4.7 ± 0.1 
6.3 ± 
0.5 
3.9 0.96 101.9 
14.3 ± 0.5 
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6.4.3. Solubility in the presence of surfactants 
Solubility of THC-Val, THC-Val-Val and THC-Val-HS in the presence of various solubilizing 
agents has been presented in Table 6-3. THC-Val-HS demonstrated significantly higher 
solubility compared to the other prodrugs tested. With cyclodextrins, THC-Val-HS demonstrated 
better solubility in RMβCD (4266.1 ± 188.8 µg/mL) compared to HPβCD (2973.5 ± 108.1 
µg/mL). Solubility of THC-Val-HS was studied in the presence of 0.1% (2721.2 ± 198.9 
µg/mL), 0.25% (3371 ± 603.3 µg/mL) and 0.5% Cremophor RH 40 (4755 ± 355.4 µg/mL). Use 
of 0.1% poloxamer 407 did not lead to a significant improvement in solubility (677.8 ± 51.7 
µg/mL). THC-Val-HS solubility was also studied in the presence of 0.1% polysorbate 80 (3163.3 
± 248.02 µg/mL) and 0.1% tyloxapol (3358.7 ± 117.3). 
 
Table 6-2: pH Dependent solubility of THC-Val-HS at pH 3, 5, 7 and 9. Results are depicted as 
mean ± SD (n=3).  
 
 
 
 
 
 
 
 
 
 
pH  
Solubility 
(µg/mL) 
Water 37.6 ± 6.6 
IPBS 97.3 ± 1.7 
3 ND* 
5 1.3 ± 0.1 
7 76.8 ± 12.9 
9 141.8 ± 32.9 
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6.4.4. Stability in the presence of Surfactants and Cyclodextrins 
The hydrolysis of THC-Val-HS followed first order degradation. Apparent first order 
hydrolysis rate constants and half-life of THC-HG in the presence of surfactants is presented in 
Table 6-4. No degradation was observed in the presence of HPβCD at 4 °C and 25 °C.  
6.4.5. Corneal Permeability Studies 
In vitro permeability studies for THC-Val and THC-Val-Val were carried out in the 
presence of RMβCD 2.5%, Cremophor RH 40 0.5%, Polysorbate 80 0.1% and Tyloxapol 0.1%. 
Permeability of THC-Val in the presence of 2.5% RMβCD was found to be 4.75 x 10-6 cm/s. No 
drug was detected in the receiver chamber from the other THC-Val formulations.  THC-Val-Val 
was not detected in the receiver chamber with any of the formulations studied.  
Since THC-Val-HS demonstrated significantly higher solubility, lower concentrations of 
the solubilizers were used in the in vitro studies. Permeability of THC-Val-HS (Fig. 6-2) was 
found to be highest in 1.5% HPβCD (14.3 x 10-6 cm/s). Transcorneal permeability was 
significantly lower in 1.5% RMβCD (6.5 x 10-6 cm/s) and in the presence of surfactants. 
However, no significant difference in the permeability of THC-Val-HS was found between 
0.05% polysorbate 80 (4.06 x 10
-6
 cm/s), 0.05% tyloxapol (3.1 x 10
-6
 cm/s) and 0.05% 
Cremophor RH 40 (3.16 x 10-6 cm/s). 
BAK (0.02%) and EDTA (0.1%) are commonly used preservatives/preservative aids in 
ophthalmic formulations. Thus, permeability of 0.05% Cremophor RH 40 with 0.02% BAK and 
0.1% EDTA was also studied.  
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 Table 6-3: Solubility of THC-Val, THC-Val-Val and THC-Val-HS in different surfactant 
solutions at 25 °C. Results are depicted as mean ± SD (n=3).  
 
 Table 6-4: Apparent first order rate constants (k* x 105, h-1) and half lives (t1/2, days) of THC-
Val-HS in hydroxylpropyl beta cyclodextrin (HPβCD) and Cremophor RH 40 in IPBS at 4 °C, 
25 °C and 40 °C.  Results are depicted as mean ± SD (n=3).  
ND* - No degradation observed for 2 weeks 
Excipient 
Concentration       
% w/v 
Solubility (µg/mL) 
THC-Val THC-Val-Val THC-Val-HS 
Plain IPBS - < 1 µg/mL < 1 µg/mL 96.3 ± 1.1 
HPβCD 2.5 32.2 ± 2.5 32.3 ± 1.1 2973.5 ± 108.1 
RMβCD 2.5 191.7 ± 1.1 179.1 ± 1.9 4266.1 ± 188.8 
Cremophor RH 
40 
0.1 181.6 ± 11.5 178.1 ± 7.5 2721.2 ± 198.9 
0.25 443.6 ± 7.9 393.2 ± 10.1 3371 ± 603.3 
0.5 676.5 ± 38.8 632.1 ± 32.2 4755 ± 355.4 
Poloxamer 188 0.1 0.85 ± 0.1 1.4 ± 0.1 - 
Poloxamer 407 0.1 26.4 ± 5.7 4.9 ± 1.1 677.8 ± 51.7 
Polysorbate 80 0.1 105.4 ± 17.9 179.4 ± 4.1 
3163.3 ± 
248.02 
Tyloxapol 0.1 67.4 ± 3.3 130.4 ± 4.5 3358.7 ± 177.3 
Formulation 
Concentratio
n  (%w/v) 
 
4 °C 25 °C 40 °C 
HPβCD  
2.5 
k 
ND* ND* 
196.4 ± 3.6 
t1/2 14.7 ± 0.3  
5 
k 
ND* ND* 
58.4 ± 3.4 
t1/2 49.6 ± 2.9 
Cremophor RH 40  0.1 
k 49.6 ± 0.2 45.8 ± 9.2 51.3 ± 11.5 
t1/2 58.3 ± 0.2 65.7 ± 13.2 59.1 ± 12.8 
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6.4.6. In Vivo Bioavailability Studies 
Based on the in vitro data, a cyclodextrin and a surfactant formulation were selected for 
the in vivo bioavailability studies. HPMC (0.5%) was added to the selected formulations to 
increase precorneal contact time. In vivo bioavailability studies were carried out for a period of 
one hour post topical instillation. The better formulation was then selected for a three hour time 
period study. Ocular penetration of THC-Val-HS from a polymeric film formulation was also 
studied.  
THC-Val-HS when formulated in 2.5% HPβCD and 0.5% HPMC led to significant 
increase in the amount of THC reaching the aqueous humor (69.4 ± 16.7 ng/100 µL) and iris 
ciliary body (65.8 ± 15.9 ng/50 mg). When the HPβCD in the formulation was increased to 5% at 
double the prodrug concentration, a significant decrease in THC concentrations was observed in 
the aqueous humor (31.3 ± 13.4 ng/100 µL) but not in the iris ciliary body (50.2 ± 9.9 µg/mL). 
However, THC concentrations were observed to be below detection levels in the vitreous humor 
and the retina choroid in both cases. 
In vitro permeability data suggested a five-fold lower permeability of THC-Val-HS in the 
presence of Cremophor RH 40 formulation compared to HPβCD formulation. However, similar 
in vivo tissue THC concentrations were obtained in the aqueous humor (62.1 ± 12.6 ng/100 µL) 
and the iris ciliary body (51.4 ± 19.5 µg/50 mg). In this case also THC was not detected in the 
back of the eye tissues.  
Since stability of THC-Val-HS in the cyclodextrin formulation was markedly better 
compared to the cremophor formulation (Table 6-4) a three hour time period study, post 
instillation, was carried out using the cyclodextrin formulation. THC concentrations at 3 hours 
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decreased significantly in the aqueous humor (38.3 ± 10.2 ng/100 µL) but were maintained in the 
iris ciliary body (57.9 ± 16.1 ng/50 mg).  
In contrast to the earlier studies, the polymeric film was able to deliver THC to the 
aqueous humor (61.3 ± 32.1 ng/100 µL), iris ciliary body (86.03 ± 38.2 ng/50 mg) and retina 
choroid (355.5 ± 155.2 ng/50 mg). However, THC levels were below detection limits in the 
vitreous humor. At the end of 3 hours, THC concentrations decreased significantly in the 
aqueous humor (29.1 ± 14.2 nd/100µL) and retina choroid (11.9 ± 4.9 ng/50 mg) but remained 
constant in the iris ciliary body (104.2 ± 41.2) (Table 6-5).  
 
Figure 6-2: Permeability of THC-Val-HS from various surfactant solutions across isolated rabbit 
cornea at 34 °C. Receiver solution consisted of IPBS containing 2.5% HPβCD (pH 7.4). Results 
are depicted as mean ± SD (n=3-4). *p<0.05.   
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Table 6-5: Total THC concentrations observed in rabbit ocular tissues post topical administration of 50 µL of THC-Val-HS in 
2.5% HPβCD + 0.5% HPMC (0.1% w/v), 5% RMβCD (0.4% w/v), 0.1% Cremophor RH 40 + 0.1% EDTA + 0.5% HPMC or 
formulated in an hot melt extruded film. Results are depicted as mean ± SD (n=3).  
 
 
ND*- Not Detected 
Tissue 
2.5 % HPβCD + 0.5% HPMC 
5% HPβCD + 
0.5% HPMC 
0.1% Cremophor RH 
40+ 0.02% BAK + 
0.1% EDTA + 0.5% 
HPMC 
Ocular Film 
1 Hour 3 Hours 1 Hour 1 Hour 1 Hour 3 Hours 
Drug Concentration 
(% w/v) 
0.26 0.5 0.25 0.78 
Cornea 
(ng/50 mg Tissue) 
1677.1 ± 172.1 1142.3 ± 415.9 443.5 ± 152.2 1191. 7 ± 231.1 
1634.5 ± 
756.5 
1043.4 ± 
614.4 
Aqueous Humor 
(ng/100 µL) 
69.4 ± 16.7 38.3 ± 10.2 31.3 ± 13.5 62.1 ± 12.6 61.3 ± 32.1 29.1 ± 14.2 
Iris-Cilliary Body 
(ng/50 mg Tissue) 
65.8 ± 15.9 57.9 ± 16.1 50.2 ± 9.9 51.44 ± 19.5 86.03 ± 38.2 104.2 ± 41.2 
Vitreous Humor 
(ng/mL) 
ND* ND* ND* ND* ND* ND* 
Retina-Choroid 
(ng/50 mg Tissue) 
ND* ND* ND* ND* 355.5 ± 155.2 11.9 ± 4.9 
Sclera 
(ng/250 mg Tissue) 
882.2 ± 185.8 241.8 ± 106.6 191.5 ± 50.1 913.4 ± 432.9 378.2 ± 154.3 162.5 ± 100 
1
0
7
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6.5. DISCUSSION 
Glaucoma is a neurodegenerative disease characterized by a progressive and irreversible 
loss of retinal ganglion cells (RGC) which leads to vision loss(140). Control of intraocular 
pressure, although a significant risk factor, is insufficient to completely halt the progression of 
the disease.  Neuroprotection of retinal ganglion cells against apoptosis could lead to a new 
generation of antiglaucoma agents that could prevent/reduce vision loss. Δ9-
Tetrahydrocannabinol is one such molecule that could demonstrate neuroprotective activity 
independent of intraocular pressure lowering properties.  
There are however significant barriers to the development of a topical neuroprotectant for 
the treatment of glaucoma. The posterior segment of the eye is well protected by a number of 
anatomical and physiological barriers(174, 175). Access to the retina and vitreous humor is 
restricted for topically applied drugs as well as drugs administered through the systemic 
circulation.  A number of strategies have been used with limited success to target the back of the 
eye tissues(176).  Current strategy for drug delivery to the retina is invasive intravitreal 
administration of a solution/suspension or polymeric insert in the vitreous humor(159, 177). 
Non-invasive delivery to the back of the eye tissues forms a significant barrier to the delivery of 
any potentially neuroprotective agent. In addition there are no clinical models/clinically 
monitored endpoints available to determine neuroprotective effect of a drug molecule for the 
treatment of glaucoma(178). 
Following topical application, the physicochemical characteristics of the drug determine 
its permeability across the cornea. In the present study synthesis of THC prodrugs was carried 
out to improve hydrophilicity with an aim to increase intraocular delivery. Amongst all the 
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prodrugs tested, the solubility, stability and permeability values obtained with THC-Val-HS were 
markedly better than that observed with any other prodrug tested, including THC-HG which was 
evaluated in our earlier studies(148). Topically administered THC-Val-HS, as ocular eye drops, 
was able to deliver THC to the anterior segment tissues (aqueous humor and the iris ciliary body) 
but not to the retina and the vitreous humor. The results thus underline the difficulty in delivering 
drug to the back-of-the eye through the topical route. The significant vascular and lymphatic 
drainage in the sclera and choroid and the barrier characteristics of the RPE and Bruch’s 
membrane severely restrict the passage of the drug through the sclera into the retina and vitreous 
humor. Previous reports demonstrate the sclera→choroid→retina→vitreous humor is the 
principal pathway for the diffusion of the drug from the topical application site to the back-of-the 
eye.  
THC-Val-HS was incorporated in a polymeric film to improve precorneal retention time, 
provide intimate contact between the drug and the conjunctiva/sclera and to control the release of 
drug in the eye. The polymeric film allowed higher drug loading in the formulation allowing 
administration of higher doses. Unlike the other formulations tested, significantly high THC 
concentrations were observed in the retina with this dosage form. THC concentrations in the 
retina were observed even at the end of three hours post instillation. This formulation needs 
further investigation to optimize the delivery of the prodrug across the ocular barriers. The 
present study thus effectively designed an approach to deliver THC to both the anterior and the 
posterior chamber of the eye. Further studies to determine therapeutic outcomes need to be 
carried out in the future.  
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Current glaucoma therapy is based on the presumption that neurodegeneration of the 
retina is directly linked to increased intraocular pressure. However visual field loss occurs even 
after sufficient reduction of intraocular pressure has been achieved. Δ9-Tetrahydrocannabinol is a 
promising candidate that could achieve both intraocular pressure reduction and neuroprotection 
through independent mechanisms of actions. Even though early evidence of its efficacy was 
discovered four decades ago, its utility in glaucoma is unknown due to poor formulation and 
study designs.  
Δ9-Tetrahydrocannabinol is a highly lipophilic compound with very low aqueous 
solubility. A model for the high throughput screening of the corneal permeability of pro-drugs 
and formulations was developed. To improve physicochemical properties prodrugs were 
designed so as to add an ionizable group to the parent molecule. Two prodrugs, Δ9-
Tetrahydrocannabinol hemisuccinate (THC-HS) and Δ9-Tetrahydrocannabinol hemiglutarate 
(THC-HG) were synthesized. Being weak acids these prodrugs displayed improved aqueous 
solubility at physiological pH values. Additionally both prodrugs demonstrated improved 
inherent permeability in the unionized state. At physiological pH values, however, their 
permeability dropped significantly.  
Four formulation approaches were chosen to improve the solubility and permeability of 
the prodrugs at physiological pH. Since THC-HG was more stable compared to THC-HS it was 
selected for further studies. Use of cyclodextrins led to improved solubility but did not shield the 
charge on the prodrugs leading to poor permeability values at physiological pH. An ion-pair 
prodrug formulation helped to shield the charge and improved permeability. Inclusion of 
surfactants improved solubility, solution stability and permeability. Due to constraints on the 
concentration of surfactants that can be used for ophthalmic formulations, solubility could not be 
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improved beyond a certain extent. Second generation valine, valine-valine and valine-
hemisuccinate ester prodrugs of THC were synthesized to further improve physicochemical 
parameters. Screening of THC-Val and THC-Val-Val did not demonstrate favorable solubility 
and permeability characteristics and thus were not studied any further. THC-Val-HS 
demonstrated significant improvement in solubility and permeability.  
THC-HG (ion pair and micellar formulations) and THC-Val-HS (cyclodextrin and 
micellar) were instilled in an anesthetized rabbit model to determine in vivo bioavailability. THC 
formulated in mineral oil, micellar and emulsion formulation was used as controls. Intraocular 
tissues concentration of THC was found to be below detectable levels for mineral oil, micellar 
and emulsion formulations. THC-HG and THC-Val-HS were able to deliver significantly higher 
concentrations to the anterior chamber tissues (aqueous humor, and iris ciliary body) but no drug 
was detected in the vitreous humor and the retina. Incorporation of THC-Val-HS, on the other 
hand, in a polymeric film delivered THC to the aqueous humor, iris ciliary body and the retina.  
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